Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.4.3.4 - monoamine oxidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
6,7-dihydropteridine reductase deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
6-pyruvoyltetrahydropterin synthase deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Acidosis
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
Acquired Immunodeficiency Syndrome
A systematic review and meta-analysis examining the interrelationships between chemical and non-chemical stressors and inherent characteristics in children with ADHD.
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes.
Acute Kidney Injury
Effect of monoamine oxidase inhibitors on ischaemia/reperfusion-induced acute kidney injury in rats.
Sex differences in ischaemia/reperfusion-induced acute kidney injury depends on the degradation of noradrenaline by monoamine oxidase.
Adenocarcinoma
1,2,4-Oxadiazole/2-Imidazoline Hybrids: Multi-target-directed Compounds for the Treatment of Infectious Diseases and Cancer.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Adenocarcinoma of Lung
Monoamine Oxidase A Inhibits Lung Adenocarcinoma Cell Proliferation by Abrogating Aerobic Glycolysis.
Adenoma
Dissociation of thyrotropin-dependent enzyme activities, reduced iodide transport, and preserved iodide organification in nonfunctioning thyroid adenoma and multinodular goiter.
Adenoma, Islet Cell
Dopa-decarboxylase and monoamine oxidase activities in a transplantable islet cell tumor of the golden hamster.
Adrenal Hyperplasia, Congenital
Personality characteristics and platelet MAO activity in women with congenital adrenal hyperplasia (CAH).
Adrenocortical Hyperfunction
Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism.
Agranulocytosis
Medically serious adverse effects of newer antidepressants.
Airway Obstruction
Effect of exercise on serum monoamine oxidase and airway obstruction in asthmatic children.
Akathisia, Drug-Induced
SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.
Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
Albuminuria
Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy.
Alcohol Withdrawal Delirium
Monoamines, monoamine oxidase and alcoholism.
Alcohol-Related Disorders
Genetic and non-genetic influences on the development of co-occurring alcohol problem use and internalizing symptomatology in adolescence: a review.
Genetic associations with intimate partner violence in a sample of hazardous drinking men in batterer intervention programs.
Alcoholic Neuropathy
Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.
Alveolar Bone Loss
Lipopolysaccharide-induced epithelial monoamine oxidase mediates alveolar bone loss in a rat chronic wound model.
Alzheimer Disease
(S)-[18F]THK5117 brain uptake is associated with A? plaques and MAO-B enzyme in a mouse model of Alzheimer's disease.
(±)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3? Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease.
1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
3-Aryl-1-phenyl-1H-pyrazole derivatives as new multitarget directed ligands for the treatment of Alzheimer's disease, with acetylcholinesterase and monoamine oxidase inhibitory properties.
3-Coumaranone derivatives as inhibitors of monoamine oxidase.
4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.
A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
A cross-talk between A? and endothelial SSAO/VAP-1 accelerates vascular damage and A? aggregation related to CAA-AD.
A Hypothesis and Evidence That Mercury May be an Etiological Factor in Alzheimer's Disease.
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
A pilot study of low-dose L-deprenyl in Alzheimer's disease.
A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients.
A rapid thin-layer chromatography bioautographic method for detecting the monoamine oxidase inhibitors in plants.
Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death.
Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg.
Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii.
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
Additional acetyl cholinesterase inhibitory property of diaryl pyrazoline derivatives.
Aliphatic propargylamines, a new series of potent selective, irreversible non-amphetamine-like MAO-B inhibitors. Their structures, function and pharmacological implications.
Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease.
Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but Not in the Cortex.
Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro.
Alzheimer's disease modifies progenitor cell expression of monoamine oxidase B in the subventricular zone.
Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes.
Antioxidant properties of eugenol, butylated hydroxylanisole, and butylated hydroxyl toluene with key biomolecules relevant to Alzheimer's diseases-In vitro.
Aspartic acid substitutions in monoamine oxidase-A reveal both catalytic-dependent and -independent influences on cell viability and proliferation.
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant.
Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.
Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease.
Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease.
Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology.
Chemotherapy of cognitive disorders in geriatric subjects.
Cholinesterase Inhibitory Activities of Selected Halogenated Thiophene Chalcones.
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites.
Citrus spp. essential oils improve behavioral pattern, repressed cholinesterases and monoamine oxidase activities, and production of reactive species in fruit fly (Drosophila melanogaster) model of Alzheimer's Disease.
Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer's Disease in Mice, Observed by in Vivo Two-Photon Imaging.
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation.
Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.
Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease.
Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons.
Deprenyl reduces the death of motoneurons caused by axotomy.
Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-? aggregation against Alzheimer's disease.
Design, Synthesis, and Biological Evaluation of Pyridazinones Containing the (2-Fluorophenyl) Piperazine Moiety as Selective MAO-B Inhibitors.
Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Developing a Multi-target Model to Predict the Activity of Monoamine Oxidase A and B Drugs.
Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease.
Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer's type dementia.
Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease.
Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease.
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease.
Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain.
Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.
Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease.
Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option.
Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer's Disease.
Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.
Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer's Disease.
First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer's Disease.
From Anti-Parkinson's Drug Rasagilineto Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease.
G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease.
Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease.
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening.
Identifying natural compounds as multi-target directed ligands against Alzheimer's disease: an in silico approach.
In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid.
In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain.
In vitro anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida).
In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity.
Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence.
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients.
Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease.
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants.
Intra- and extraneuronal monoamineoxidase-A and -B activities after central axotomy (hemisection) on rats.
Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.
Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: a 90-month longitudinal study.
Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia.
Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells.
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.
Jasonia glutinosa (L.) DC., a Traditional Herbal Tea, Exerts Antioxidant and Neuroprotective Properties in Different In Vitro and In Vivo Systems.
KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor to Abate Alzheimer's Disease.
L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
L-deprenyl: nitric oxide production and dilation of cerebral blood vessels.
Lack of protective effect of R(-)-deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone.
Ladostigil prevents age-related glial activation and spatial memory deficits in rats.
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study.
M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
MAOA-VNTR Genotype Effects on Ventral Striatum-Hippocampus Network in Alzheimer's Disease: Analysis Using Structural Covariance Network and Correlation with Neurobehavior Performance.
Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection.
Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.
Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration.
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and ?-amyloid inhibitors for Alzheimer's disease.
Monoamine oxidase assays.
Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes.
Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study.
Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with ?-secretase and regulates neuronal amyloid ?-peptide levels.
Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients.
Monoamine Oxidase Inhibition and Molecular Modeling Studies of Piperidyl-thienyl and 2-Pyrazoline Derivatives of Chalcones.
Monoamine oxidase inhibition by Rhodiola rosea L. roots.
Monoamine oxidase inhibition by selected dye compounds.
Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review).
Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex.
Monoamine oxidase-B inhibition in Alzheimer's disease.
Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
Monoamineoxidase-B (MAO-B) Inhibitors in theTreatment of Alzheimer's and Parkinson's Disease.
Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations.
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Multi-target-directed Benzylidene-indanone derivatives: Anti-? Amyloid (A?) aggregation, Antioxidant, Metal chelation and Monoamine oxidase B (MAO-B) Inhibition Properties Against Alzheimer's disease.
Multi-targeting aurones with monoamine oxidase and amyloid-beta inhibitory activities: Structure-activity relationship and translating multi-potency to neuroprotection.
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-?-amyloid (A?) aggregation and metal chelation properties against Alzheimer's disease.
Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and ?-amyloid in aging and Alzheimer's disease.
Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against A?(1-42)-induced toxicity.
Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.
No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease.
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders.
Oxygen-glucose deprivation-induced changes in organotypic cultures of the rat hippocampus.
Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO?B inhibitors.
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Platelet MAO-B activity and vitamin B12 in old age dementias.
Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders.
Platelet serotonin and monoamine oxidase in Alzheimer's disease with psychotic features.
Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease.
Platelets: Peripheral Biomarkers of Dementia?
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Potent Selective Inhibition of Monoamine Oxidase A by Alternariol Monomethyl Ether Isolated from Alternaria brassicae.
Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens.
Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.
Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.
Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia.
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
Scouting around 1,2,3,4-Tetrahydrochromeno[3,2-c]pyridin-10-ones for Single- and Multitarget Ligands Directed towards Relevant Alzheimer's Targets.
Selegiline as immunostimulant--a novel mechanism of action?
Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's disease.
Serine 209 resides within a putative p38(MAPK) consensus motif and regulates monoamine oxidase-A activity.
Single heterocyclic compounds as Monoamine Oxidase Inhibitors: From past to present.
Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer's disease.
Substrate specificity of human platelet monoamine oxidase B activity Parkinson's and Alzheimer's disease.
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).
Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
Synthesis of Amide and Ester Derivatives of Cinnamic Acid and Its Analogs: Evaluation of Their Free Radical Scavenging and Monoamine Oxidase and Cholinesterase Inhibitory Activities.
Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.
Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors.
Synthesis, biological evaluation, and molecular modeling of nitrile-containing compounds: Exploring multiple activities as anti-Alzheimer agents.
Synthetic polyamines as potential amine oxidase inhibitors: a preliminary study.
The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity.
The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.
The cholinergic neurotoxin ethylcholine mustard aziridinium (AF64A) induces an increase in MAO-B activity in the rat brain.
The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease.
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
The neuroprotective mechanism of action of the multimodal drug ladostigil.
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease.
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.
Therapeutic Potential Of Multifunctional Derivatives Of Cholinesterase Inhibitors.
Total monoamine oxidase (MAO) inhibition by chestnut honey, pollen and propolis.
TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Type a and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study.
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.
[Effects of amiridin and tacrine, drugs effective in Alzheimer's disease, on the activity of monoamine oxidase A and B]
[Effects of Goutengsan on model of Alzheimer dementia in rats by AlCl3]
[Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells]
Amebiasis
Neurohumoral alterations and their role in amoebiasis.
Amnesia
Effect of age of habit on susceptibility to cycloheximide-induced amnesia in mice.
Involvement of serotonergic neuronal systems in the anti-amnesic action of naftidrofuryl oxalate.
Neurotransmitter Metabolic Enzymes and Antioxidant Status on Alzheimer's Disease Induced Mice Treated with Alpinia galanga (L.) Willd.
Recovery from amnesia induced by pre-test injections of monoamine oxidase inhibitors.
Role of the biogenic amines in the reversal of cycloheximide-induced amnesia.
Similar effects of a monoamine oxidase inhibitor and a sympathomimetic amine on memory formation.
Some characteristics of amnesia induced by FLA-63 an inhibitor of dopamine beta hydroxylase.
Amyotrophic Lateral Sclerosis
18F-THK5351 PET Can Identify Core Lesions in Different Amyotrophic Lateral Sclerosis Phenotypes.
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.
A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1(G93A) ALS Mice.
Association of monoamine oxidase B alleles with age at onset in amyotrophic lateral sclerosis.
Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis.
Monoamine oxidase-B in astrocytes.
Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography.
Monoamine oxidase-B in motor cortex: changes in amyotrophic lateral sclerosis.
Rasagiline for Amyotrophic Lateral Sclerosis: a Randomized Controlled Trial.
Reactive gliosis and monoamine oxidase B.
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Anaphylaxis
Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.
[Action of reserpine and monoamine oxidase inhibitors on anaphylactic shock in mice.]
[CRITICAL STUDIES ON THE SIGNIFICANCE OF SEROTONIN IN THE MECHANISM OF ANAPHYLAXIS. 2. CHANGES IN THE SEROTONIN CONTENT AND MONOAMINE OXIDASE ACTIVITY OF TISSUE IN ANAPHYLACTIC SHOCK.]
Anemia
Fermented Goat Milk Consumption Enhances Brain Molecular Functions during Iron Deficiency Anemia Recovery.
Human platelet monoamine oxidase activity in health and disease: a review.
Iron deficiency anemia and catecholamine metabolism.
Proceedings: Reduction of platelet monoamine oxidase activity in iron deficiency anaemia.
Anemia, Iron-Deficiency
Human platelet monoamine oxidase activity in health and disease: a review.
Human platelet monoamine oxidase activity in iron-deficiency anaemia.
Iron deficiency anemia and catecholamine metabolism.
Proceedings: Reduction of platelet monoamine oxidase activity in iron deficiency anaemia.
Some properties of human platelet monoamine oxidase in iron-deficiency anaemia.
Anemia, Megaloblastic
Human platelet monoamine oxidase activity in health and disease: a review.
Platelet monoamine oxidase activity in megaloblastic anaemia.
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.
Anemia, Pernicious
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.
Aneurysm
Association between semicarbazide-sensitive amine oxidase, a regulator of the glucose transporter, and elastic lamellae thinning during experimental cerebral aneurysm development: laboratory investigation.
Systemic reactions to ophthalmic drug preparations.
Aneurysm, Dissecting
Hypertensive emergencies. Etiology and management.
Angina Pectoris
A basis for the use of monoamine oxidase inhibitors in angina pectoris.
A trial of a new monoamine oxidase inhibitor in angina pectoris.
Attenuation of cardiovascular responses to exercise as a possible basis for effectiveness of monoamine oxidase inhibitors in angina pectoris.
Clinical trials with a new monoamine oxidase inhibitor--nialamide in the treatment of angina pectoris.
Experiences in the treatment of angina pectoris with monoamine oxidase inhibitors.
Monoamine oxidase inhibitors and angina pectoris.
Monoamine oxidase inhibitors in the treatment of angina pectoris.
On the mechanism of action of monoamine oxidase inhibitors in angina pectoris.
Present status of monoamine oxidase inhibitors in angina pectoris.
The use of monoamine oxidase inhibitors as adjuncts in the treatment of hypertension and angina pectoris.
Treatment of angina pectoris with a new monoamine oxidase inhibitor, pivalybenzydrazine.
[ANGINA PECTORIS AND MONOAMINE OXIDASE INHIBITORS.]
[Iproniazid and other inhibitors of monoamine oxidase in the treatment of angina pectoris.]
[Iproniazid and other monoamine oxidase inhibitors in the treatment of angina pectoris.]
[Monoamine oxidase inhibitor in the treatment of angina pectoris.]
[Monoamine oxidase inhibitors in the treatment of angina pectoris.]
[Notes on the treatment of angina pectoris with a new monoamine oxidase inhibitor (M.A.O.I.)]
[On the action of monoamine oxidase inhibitors in angina pectoris.]
[On the treatment of angina pectoris with monoamine oxidase inhibitors.]
[SIGNIFICANCE OF MONOAMINE OXIDASE INHIBITORS IN THE TREATMENT OF ANGINA PECTORIS.]
[Thrombocyte functional resistance and histamine and serotonin metabolism in ischemic heart disease]
[TREATMENT OF ANGINA PECTORIS WITH MONOAMINE OXIDASE INHIBITORS.]
Anhedonia
The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia.
Anthracosilicosis
[Cytochemical parameters in studying the body at peripheral hemopoiesis level]
Aortic Aneurysm
Role of the media in vascular injury: atherosclerosis and dissection.
Aortic Rupture
Beta-aminopropionitrile-induced aortic ruptures in turkeys: inhibition by reserpine and enhancement by monoamine oxidase inhibitors.
Aortic Valve Stenosis
Semicarbazide-Sensitive Amine Oxidase Increases in Calcific Aortic Valve Stenosis and Contributes to Valvular Interstitial Cell Calcification.
Aphasia
The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia.
Aphasia, Primary Progressive
Neuroinflammation is highest in areas of disease progression in semantic dementia.
Appendicitis
[Monoamine oxidase activity in the appendicitis (one cause of various post-appendectomy complaints)]
aromatic-l-amino-acid decarboxylase deficiency
A female case of aromatic l-amino acid decarboxylase deficiency responsive to MAO-B inhibition.
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Arrhythmias, Cardiac
Ectopic ventricular rhythms and myocardial infarction in the domestic pig and their response to nialamide, a monoamine oxidase inhibitor.
Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
The role of monoamine oxidase inhibitors in experimental auricular arrhythmia.
Arteritis
[Action of a monoamine oxidase inhibitor (Niamid) on various experimental vascular lesions in the rabbit (allergic arteritis, myocardial necrosis caused by isoproterenol, aortic medionecrosis, venous and arterial thrombosis).]
Arthritis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
[Changes in the monoamine oxidase activity in experimental myocarditis and arthritis in rats thymectomized at birth]
[Changes in the monoamine oxidase activity of neonatally thymectomized rats with experimental myocarditis and arthritis]
Arthritis, Rheumatoid
Monoamine oxidase inhibitors for IgA nephropathy.
Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors.
Serotonin metabolism and its enzymic activities in joint diseases.
The level of serum monoamine oxidase in rheumatoid arthritis.
Tryptophan metabolism in the joint diseases.
[Activity of serum monoamine oxidase in rheumatic fever and rheumatoid arthritis]
[Preliminary study on the clinical effects of a new monoamine oxidase antagonist in rheumatoid arthritis.]
Arthus Reaction
Serotonin metabolism in the arthus reaction.
Ascorbic Acid Deficiency
Dietary ascorbic acid deficiency in guinea pigs: no effect on ethanol preference, spiroperidol binding, or monoamine oxidase activity.
Asthma
Clinical contraindications to allergen immunotherapy: an EAACI position paper.
Monoamine oxidase activity in serum of patients with bronchial asthma and healthy subjects.
Personality and illness: Genetic connections?
THE RISKS OF MONOAMINE OXIDASE INHIBITORS IN THE TREATMENT OF BRONCHIAL ASTHMA.
[Arterial hypertension in chronic bronchial obstruction and various problems of its treatment]
[Behavior of serum monoamine oxidase (MAO) as well as the excretion of urinary 5-hydroxyindole-acetic acid (5-HIA) in healthy subjects and in children with allergic bronchial asthma]
[Hemodynamics, serotonin and monoamine oxidase in bronchial asthma and systemic arterial hypertension]
[Monoamine oxidase activity in serum of patients with asthma and in elderly subjects]
[Myocardial status, hemodynamics and pressor humoral substances in patients with bronchial asthma and arterial hypertension]
[Serum monoamine oxidase activity in patients with bronchial asthma and in healthy subjects]
Astrocytoma
Antioxidant defense against antidepressants in C6 and 1321N1 cells.
Catechol-O-methyl transferase and monoamine oxidase activity in cultured rodent astrocytoma cells.
Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene.
Monoamine oxidase B activity is increased in human gliomas.
Monoamine oxidase-B in astrocytes.
[Comparative study of the effect of inhibitors of monoamine oxidase and ftorafur on the growth of de-differentiated astrocytoma]
[Development of experimental brain tumors in modulated amine metabolism]
Atherosclerosis
Determination of human serum semicarbazide-sensitive amine oxidase activity: a possible clinical marker of atherosclerosis.
Disruption of phactr-1 pathway triggers pro-inflammatory and pro-atherogenic factors: New insights in atherosclerosis development.
Endogenous formaldehyde as a potential factor of vulnerability of atherosclerosis: involvement of semicarbazide-sensitive amine oxidase-mediated methylamine turnover.
Inactivation of semicarbazide-sensitive amine oxidase induces the phenotypic switch of smooth muscle cells and aggravates the development of atherosclerotic lesions.
Inhibition of semicarbazide-sensitive amine oxidase reduces atherosclerosis in apolipoprotein E-deficient mice.
Inhibition of Semicarbazide-sensitive Amine Oxidase Reduces Atherosclerosis in Cholesterol-fed New Zealand White Rabbits.
Monoamine oxidase A genotype, childhood trauma, and subclinical atherosclerosis: a twin study.
Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure.
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis.
Serum vascular adhesion protein-1 level is higher in smokers than non-smokers.
Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.
[Administration of monoamine oxidase inhibitors in experimental atherosclerosis]
[Disorders of the deamination of nitrogenous compounds in the heart muscle in experimental atherosclerosis]
[Effect of the monoamine oxidase inhibitor--Iprazid, on the functional state of the thyroid gland in healthy rabbits and in rabbits with experimental atherosclerosis]
[Relations between catecholamines, monoamine oxidase activity and atherosclerosis in swine]
[Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells]
Atrial Fibrillation
Effect of nialamide, a monoamine oxidase inhibitor, on acetylcholine-adrenaline induced atrial fibrillation in normal & reserpinized dogs.
Metabolic alterations in rat myocardium in experimental acute atrial fibrillation.
Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation.
Plasma Catecholamine Levels on the Morning of Surgery Predict Post-Operative Atrial Fibrillation.
Atrioventricular Block
Practical considerations for the treatment of elderly patients with migraine.
Bacterial Infections
Effects of monoamine oxidase inhibitors on bacterial infections.
[On the effect of monoamine oxidase inhibitors on bacterial infection]
Basal Ganglia Diseases
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
beta-Mannosidosis
Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.
Blister
Altered catecholamine synthesis and degradation in the epidermis of patients with atopic eczema.
Bradycardia
Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor.
Brain Diseases
A direct continuous fluorometric turn-on assay for monoamine oxidase B and its inhibitor-screening based on the abnormal fluorescent behavior of silole.
Three -(pyridin-2-yl)-2-(pyridin-2-ylimino)thiazolidin-4-one as a novel inhibitor of cerebral MAO-B activity with antioxidant properties and low toxicity potential.
[Experimental studies of the pathomechanism of portal encephalopathy. I. Changes in monoamine oxidase (MAO) activity in the cerebral cortex and cerebellum of rats after portacaval shunt]
[Experimental studies of the pathomechanism of portal encephalopathy. II. Monoamine oxidase (MAO) activity in the rat brain after porta- caval shunt using 2 different methods]
Brain Edema
Quantitative evaluation of brain edema by radionuclide imaging technique.
[Neuroprotective effect of monoamine oxidase monoclonal antibody against vasogenic brain edema in rats]
Brain Injuries
Attenuation of Ischemic Stroke-Caused Brain Injury by a Monoamine Oxidase Inhibitor Involves Improved Proteostasis and Reduced Neuroinflammation.
Monoamine oxidase-B activity is not involved in the neuroinflammatory response elicited by a focal freeze brain injury.
Vascular adhesion protein-1 in human ischaemic stroke.
Brain Injuries, Traumatic
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Prefrontal cortex lesions and MAO-A modulate aggression in penetrating traumatic brain injury.
Brain Ischemia
Chronic methamphetamine administration inhibits cerebral ischemia-induced hyperactivity in Mongolian gerbils.
Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.
Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes.
Possible therapeutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional disturbances, assessed in animal models of depression.
[Properties of monoamine oxidase in the brain of mongolian gerbils during cerebral ischemia]
Brain Neoplasms
Monoamine oxidase B activity is increased in human gliomas.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.
Site-specific expression of amine oxidases in breast cancer metastases.
[Histochemical demonstration of monoamine oxidase in brain tumors.]
Breast Neoplasms
Amine oxidase activities in chemically-induced mammary cancer in the rat.
Amine oxidase activities in rat breast cancer induced experimentally with 7,12-dimethylbenz(alpha)anthracene.
Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
Estrogen-related receptors-stimulated monoamine oxidase B promoter activity is down-regulated by estrogen receptors.
Mental adaptation to cancer: depression and blood platelet monoamine oxidase activity in breast cancer patients.
Monoamine oxidase-A activity is required for clonal tumorsphere formation by human breast tumor cells.
Platelet monoamine oxidase and phenolsulphotransferase M and P in cancer.
Psychiatric morbidity and platelet monoamine oxidase activity in cancer patients.
Site-specific expression of amine oxidases in breast cancer metastases.
The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Brief, Resolved, Unexplained Event
Serotonin transporter role in identifying similarities between SIDS and idiopathic ALTE.
Bronchiectasis
[Correlation between the changes in serotonin content, monoamine oxidase activity and the mast cell number in the lung tissue in bronchiectasis]
Bronchitis
[Arterial hypertension in chronic bronchial obstruction and various problems of its treatment]
Bronchitis, Chronic
[Change in monoamine oxidase activity in chronic bronchitis]
Bruxism
Experimental aggression and bruxism in rats.
Carcinogenesis
Application of novel pH sensitive isoniazid-heptamethine carbocyanine dye conjugates against prostate cancer cells.
Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenetic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
Induction of monoamine oxidase B by 17 beta-estradiol in the hamster kidney preceding carcinogenesis.
Kava root extracts hinder prostate cancer development and tumorigenesis by involvement of dual inhibition of MAO-A and LSD1.
MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.
Monoamine Oxidase A is a Major Mediator of Mitochondrial Homeostasis and Glycolysis in Gastric Cancer Progression.
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Monoamine oxidase B inhibitor enhances experimental carcinogenesis in rat colon induced by azoxymethane.
The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment.
Carcinoid Tumor
Biochemical and ultrastructural differences between muco-epidermoid and carcinoid tumors of the bronchus.
Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine.
Monoamine and diamine oxidase activity in the diagnosis of carcinoid tumors.
Monoamine oxidase deficiency: a cause of symptomatic hyperserotoninemia in the absence of carcinoid.
[EXPERIMENTAL CONTRIBUTION TO THE STUDY OF CARCINOID SYNDROME. ON THE PARENCHYMAL LESIONS INDUCED BY PROLONGED ADMINISTRATION OF 5-HYDROXYTRYPTAMINE ASSOCIATED WITH A MONOAMINE OXIDASE INHIBITOR.]
Carcinoma
A study of some mitochondrial and peroxisomal enzymes in human colonic adenocarcinoma.
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma.
Cudarflavone B provides neuroprotection against glutamate-induced mouse hippocampal HT22 cell damage through the Nrf2 and PI3K/Akt signaling pathways.
Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1? signaling.
Effect of testosterone and 6-hydroxydopamine treatment on the metabolism of catecholamine and 5-hydroxytryptamine in methylcholanthrene-induced prostate carcinoma of rats.
Histochemical studies of monoamine oxidase in carcinoma of uterine cervix.
Monitoring treatment of pulmonary carcinomas by serial determination of monoamine oxidase and diamine oxidase in blood serum.
Monoamine oxidase (MAO) activity and its forms in normal and pathological human thyroid tissues.
Monoamine oxidase activity in the argentaffin carcinoma syndrome.
Monoamine Oxidase B in Renal Cell Carcinoma.
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Th2 response of human peripheral monocytes involves isoform-specific induction of monoamine oxidase-A.
Water-Soluble Near-Infrared Fluorescent Probes for Specific Detection of Monoamine Oxidase A in Living Biosystems.
Carcinoma, Ductal
Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
Histochemically demonstrable enzyme activities and their independence of the hormone receptor content in female breast carcinoma.
Carcinoma, Ehrlich Tumor
Monoamine oxidase activity in Ehrlich ascites tumor.
Carcinoma, Embryonal
Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells.
Carcinoma, Hepatocellular
Assignment of genes for human monoamine oxidases A and B to the X chromosome.
Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene.
Degradation of transplanted rat liver mitochondrial-outer-membrane proteins in hepatoma cells.
Differences in the structures of monoamine oxidases A and B in rat clonal cell lines.
Distinct forms of monoamine oxidase expressed in hepatoma and HeLa cells in culture.
Electrophoretic characterization of monoamine oxidase by [3H]pargyline binding in rat hepatoma cells with A and B activity.
Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug.
Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain.
Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling.
SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs.
Stephtetrandrine A-D, bisbenzylisoquinoline alkaloids from Stephania tetrandra.
[Lipid dependence of mitochondrial monoamine oxidase from rat hepatoma 27 with the use of rat liver lipid exchange proteins]
[Monoamine oxidase activity of nuclear membranes of liver and ascites hepatoma cells]
[Monoamine oxidase activity of the plasma membranes of liver and ascites hepatoma cells in rats]
[Use of protein-mediated lipid exchange for studies of membrane-bound enzymes. Properties of monoamine oxidase activated by phosphatidylcholine]
Carcinoma, Medullary
Serotonin metabolism and platelet monoamine oxidase activity in patients with medullary carcinoma of the thyroid and pheochromocytoma.
Carcinoma, Non-Small-Cell Lung
Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.
Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
The role of monoamine oxidase A in HPV-16 E7-induced epithelial-mesenchymal transition and HIF-1? protein accumulation in non-small cell lung cancer cells.
Carcinoma, Renal Cell
Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma.
Monoamine Oxidase B in Renal Cell Carcinoma.
Carcinosarcoma
[Experimental data to substantiate the antitumor action of hydrazine sulfate]
Cardiomegaly
Contribution of gene-modified mice and rats to our understanding of the cardiovascular pharmacology of serotonin.
Effects of monoamine oxidase inhibitors on isoproterenol-induced cardiomegaly in rats.
Monoamine oxidase inhibition and furazolidone-induced cardiomyopathy in turkey poults.
Monoamine oxidase inhibitors protect against coronary heart disease in rodent rat models: A pilot study.
Cardiomyopathies
Effects of a hydrazine monoamine oxidase inhibitor (phenelzine) on isoproterenol-induced myocardiopathies in the rat.
Monoamine oxidase inhibition and furazolidone-induced cardiomyopathy in turkey poults.
Monoamine Oxidase Is Overactivated in Left and Right Ventricles from Ischemic Hearts: An Intriguing Therapeutic Target.
OBSERVATIONS ON HISTOCHEMICAL DIFFERENTIAL DIAGNOSIS BETWEEN PRIMARY AND SECONDARY CARDIOMYOPATHIES. BEHAVIOR OF MONOAMINE OXIDASE, PHOSPHORYLASE, AND GLYCOGEN IN HEART MUSCLE.
p53-PGC-1? Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice.
Cardiotoxicity
A study of package inserts of potentially toxic drugs.
Allylamine cardiotoxicity: III. Protection by semicarbazide and in vivo derangements of monoamine oxidase.
Hypothermia in a combined intoxication with doxepin and moclobemide in an adolescent.
Interfaces of psychopharmacology and cardiology--part one.
Interfaces of psychopharmacology and cardiology--Part two.
The Determining Role of Mitochondrial Reactive Oxygen Species Generation and Monoamine Oxidase Activity in Doxorubicin-Induced Cardiotoxicity.
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.
[Effects on the micro-electrocardiogram of a monoamine oxidase inhibitor. Study of the cardiotoxicity of phenelzine in the chick embryo "in situ". Possible therapeutic repercussions in patients with coronary disease]
Cardiovascular Diseases
Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: Pathophysiological and therapeutic implications (Review).
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Antiglycation, radical scavenging, and semicarbazide-sensitive amine oxidase inhibitory activities of acetohydroxamic acid in vitro.
Clinical application of the monoamine oxidase inhibitors in cardiovascular disease.
Clinical contraindications to allergen immunotherapy: an EAACI position paper.
Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease.
Monoamine oxidase A genotype, childhood trauma, and subclinical atherosclerosis: a twin study.
Multifunctional compounds in the extract from mature seeds of Vicia faba var. minor: Phytochemical profiling, antioxidant activity and cellular safety in human selected blood cells in in vitro trials.
The Effect of Bilateral Nephrectomy on Renalase and Catecholamines in Hemodialysis Patients.
The importance of the monoamine oxidase inhibitors in cardiovascular disease.
[Clinical aspects and pathogenesis of the "on-off" phenomenon in Parkinson syndrome]
[The therapeutic effect of monoamine oxidase inhibitors in cardiovascular diseases.]
Carotid Artery Diseases
Inactivation of Semicarbazide-Sensitive Amine Oxidase Stabilizes the Established Atherosclerotic Lesions via Inducing the Phenotypic Switch of Smooth Muscle Cells.
Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis.
Catalepsy
Psychopharmacological investigation of the monoamine oxidase inhibitory activity of molindone, a dihydroindolone neuroleptic.
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease.
[ Anticataleptic effect of delta sleep-inducing peptide and its action on brain monoamine oxidase in rats genetically predisposed to catalepsy]
[Brain monoamine oxidase and the predisposition for catalepsy in tame and aggressive Norway rats]
Cataplexy
Cataplexy and monoamine oxidase deficiency in Norrie disease.
Catatonia
Genetic predisposition to catatonic behaviour and methylphenidate sensitivity in rats.
The mechanism of the potentiating effect of antidepressant drugs on the protective influenc oe of diphenhydramine in experimental catatonia. The role of histamine.
Central Nervous System Diseases
Discovery and optimization of 3-thiophenylcoumarins as novel agents against Parkinson's disease: Synthesis, in vitro and in vivo studies.
Elevated brain monoamine oxidase activity in SIV and HIV neurological disease.
Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B.
Central Nervous System Infections
Elevated brain monoamine oxidase activity in SIV and HIV neurological disease.
Cerebellar Ataxia
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Cerebral Amyloid Angiopathy
A cross-talk between A? and endothelial SSAO/VAP-1 accelerates vascular damage and A? aggregation related to CAA-AD.
The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease.
Cerebral Hemorrhage
[Report on a intracerebral hemorrhage after long term treatment with a monoamine oxidase inhibitor (MAO)]
Cerebrovascular Disorders
Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity.
The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity.
Chemical and Drug Induced Liver Injury
Tyramine oxidase activity in needle biopsy of normal livers and diseased livers.
Cholangiocarcinoma
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events.
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth.
Cholestasis
Metabolic changes in rat brain histaminergic neurons during subhepatic cholestasis.
[Metabolic changes in rat brain histaminergic neurons in dynamics of subhepatic cholestasis]
Chorea
Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls.
Choriocarcinoma
Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat.
Monoamine oxidase in rat placenta, human placenta, and cultured choriocarcinoma.
Cluster Headache
Concentration and uptake of 5-hydroxytryptamine in platelets from cluster headache and migraine patients.
Kinetics and thermolability of platelet monoamine oxidase in cluster headache and migraine.
Low platelet monoamine oxidase activity in headache: no correlation with phenolsulphotransferase, succinate dehydrogenase, platelet preparation method or smoking.
Migraine and cluster headache: links between platelet monoamine oxidase activity, smoking and personality.
Monoamine oxidase activities in patients with migraine or with cluster headache during the acute phases and after treatment with L-5-hydroxytryptophan.
Collagen Diseases
[1. ON SKIN TESTS. SKIN TESTS AND CLINICAL EFFECTIVENESS IN PATIENTS WITH ALLERGIC AND COLLAGEN DISEASES. 2. INFLUENCE OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN ANTAGONISTS. 3. RELATION TO CATECHOLAMINES.]
[Clinical significances of monoamine oxidase (MAO) activities in various collagen diseases (author's transl)]
Colonic Neoplasms
Reliability, decision rules, and the value of repeated tests.
Colorectal Neoplasms
Antidepressants and colorectal cancer: A population-based nested case-control study.
Monoamine Oxidase B Expression Correlates with a Poor Prognosis in Colorectal Cancer Patients and Is Significantly Associated with Epithelial-to-Mesenchymal Transition-Related Gene Signatures.
Coma
Hypothermia in a combined intoxication with doxepin and moclobemide in an adolescent.
Phenelzine toxicity responsive to dantrolene.
Ping Pong gaze in reversible coma due to overdose of monoamine oxidase inhibitor.
Similarity between tyramine-induced neurotoxicity and the coma of Reye's syndrome.
Confusion
(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
90 years of monoamine oxidase: some progress and some confusion.
Associations between platelet monoamine oxidase-B activity and acquired colour vision loss in a fish-eating population.
Monoamine oxidase inhibitors and anaesthesia. A review.
Connective Tissue Diseases
Evaluation of serum monoamine oxidase in patients with connective tissue diseases.
[Activity of serum monoamine oxidase (SMAO) in patients with connective tissue diseases : preliminary results]
Coronary Artery Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Coronary artery disease: the use of monoamine oxidase inhibitors in the treatment of the anginal syndrome.
Coronary Disease
Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease.
MONOAMINE OXIDASE INHIBITOR (TERSAVID) IN CORONARY HEART DISEASE.
Monoamine oxidase inhibitors protect against coronary heart disease in rodent rat models: A pilot study.
[Effects on the micro-electrocardiogram of a monoamine oxidase inhibitor. Study of the cardiotoxicity of phenelzine in the chick embryo "in situ". Possible therapeutic repercussions in patients with coronary disease]
[Preliminary clinical observations on treatment with a monoamine oxidase antagonist in coronary diseases and in other disease states.]
Coronary Occlusion
Myocardial interstitial levels of serotonin and its major metabolite 5-hydroxyindole acetic acid during ischemia-reperfusion.
Cough
Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors.
Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
Modulation of capsaicin induced airway reflexes in humans: effect of monoamine oxidase inhibition.
New recombinant cyclohexylamine oxidase variants for deracemization of secondary amines by orthogonally assaying designed mutants with structurally diverse substrates.
COVID-19
Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection.
Craniocerebral Trauma
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Drug therapy of hypertensive crises.
Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration.
[Brain monoamine oxidase in craniocerebral trauma]
Crohn Disease
Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression.
Monoamine oxidase inhibitors for IgA nephropathy.
Cysts
On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals.
Deafness
Isolation of a candidate gene for Norrie disease by positional cloning.
Dehydration
Phytochemicals and Enzyme Inhibitory Capacities of the Methanolic Extracts from the Italian Apple Cultivar Mela Rosa dei Monti Sibillini.
Studies of the in vitro oxidation of 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine by human monoamine oxidases A and B.
Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite.
[Effect of hydration and dehydration of the bodies of animals on bioenergetic and mediator processes in the neurosecretory cells of the anterior hypothalamus]
Delirium
Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection.
Withdrawal phenomena associated with antidepressant and antipsychotic agents.
Dementia
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy.
Ameliorative Effect of Trans-sinapic Acid and its Protective Role in Cerebral Hypoxia of Aluminium Chloride Induced Dementia of Alzheimer’s Type
Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study.
Bamboo leaf extract improves spatial learning ability in a rat model with senile dementia.
Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.
Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease.
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
Depression and senile dementia of the Alzheimer type: a role for moclobemide.
Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer's type dementia.
Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
Effects of selegiline alone or with donepezil on memory impairment in rats.
Expression of monoamine oxidase B activity in astrocytes of senile plaques.
Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type.
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Maintenance therapies for late-life recurrent major depression: research and review circa 1995.
Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease).
Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.
N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.
New Frontiers in Selective Human MAO-B Inhibitors.
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication, and disease.
Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Platelet MAO-B activity and vitamin B12 in old age dementias.
Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders.
Platelet monoamine oxidase B activity and vitamin B12 in dementia.
Platelet monoamine oxidase B activity in dementia. A 4-year follow-up.
Platelet monoamine oxidase, plasma dopamine beta-hydroxylase activity, dementia and family history of alcoholism in chronic alcoholics.
Platelets: Peripheral Biomarkers of Dementia?
Recognition and treatment of depression in Alzheimer's disease.
Selegiline in the treatment of mild to moderate Alzheimer-type dementia.
The management of coexisting depression in patients with dementia: potential of calcium channel antagonists.
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study.
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.
Dementia, Multi-Infarct
Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Dementia, Vascular
Drugs and vascular dementia.
Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia.
Platelet MAO-B activity and vitamin B12 in old age dementias.
Demyelinating Diseases
Five decades of cuprizone, an updated model to replicate demyelinating diseases.
Dengue
Studies of platelet monoamine oxidase activity in Epstein-Barr and dengue virus infections.
Depression, Postpartum
Abnormal platelet 5-hydroxytryptamine uptake and imipramine binding in postnatal dysphoria.
Elevated brain monoamine oxidase A binding in the early postpartum period.
Relationship of monoamine oxidase-A distribution volume to postpartum depression and postpartum crying.
Dermatitis, Atopic
Cofactor levels of mono- and diamine oxidase in atopic eczema.
Monoamine and diamine oxidase activities in atopic eczema.
Pathological changes in platelet histamine oxidases in atopic eczema.
[Histamine degrading enzymes in atopic eczema]
[Monoamine oxidase activity of the skin in patients with disseminated neurodermatitis]
Diabetes Complications
Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications.
Antiglycation, radical scavenging, and semicarbazide-sensitive amine oxidase inhibitory activities of acetohydroxamic acid in vitro.
Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet.
Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia.
Protective effects of the novel amine-oxidase inhibitor multi-target drug SZV 1287 on streptozotocin-induced beta cell damage and diabetic complications in rats.
Simultaneous determination of formaldehyde and methylglyoxal in urine: involvement of semicarbazide-sensitive amine oxidase-mediated deamination in diabetic complications.
Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema.
Diabetes Insipidus
[Age-dependent changes in brain monoamine oxidase in Brattleboro rats with genetically determined diabetes insipidus]
Diabetes Mellitus
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus.
Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis.
Effects of diabetes mellitus and chemical sympathectomy on tissue monoamine oxidase activity and norepinephrine concentration in the golden hamster.
Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy.
Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus.
Increased activity of serum amine oxidases in granuloma annulare, necrobiosis lipoidica and diabetes.
Patient selection in ambulatory anesthesia - an evidence-based review: part II.
Physiological and pathological influences on serum monoamine oxidase level. Effect of age, sex, contraceptive steroids and diabetes mellitus.
Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin.
Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus.
Production of a truncated soluble human semicarbazide-sensitive amine oxidase mediated by a GST-fusion protein secreted from HEK293 cells.
Serum monoamine oxidase (MAO) in diabetes mellitus and some other internal diseases.
Studies on semicarbazide-sensitive amine oxidase in patients with diabetes mellitus and in transgenic mice.
The effect of diabetes mellitus on the morphology and physiology of monoamine oxidase in the pancreas.
The effects of type 1 diabetes mellitus and of tobacco smoke on dissipation of catecholamines in pulmonary endothelial cells--a non-neuronal site of uptake1.
Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.
[Blood serum monoamine oxidase and ceruloplasmin activity in diabetes mellitus]
[Value of the use of monoamine oxidase inhibitors in the treatment of diabetes mellitus]
Diabetes Mellitus, Experimental
Changes in monoamine oxidase activity in rat brain during alloxan diabetes.
The effects of anxiogenic stress on glucocorticoid sensitivity, glucose tolerance, and alloxan resistance in rats.
Diabetes Mellitus, Type 1
A high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type 1 diabetes.
Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride.
Glycaemic control by monoamine oxidase inhibition in a patient with type 1 diabetes.
Monoamine Oxidase Inhibition in a Patient With Type 1 Diabetes and Depression.
Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia.
Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin.
The effects of type 1 diabetes mellitus and of tobacco smoke on dissipation of catecholamines in pulmonary endothelial cells--a non-neuronal site of uptake1.
Diabetes Mellitus, Type 2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus.
Bioactive and functional properties of sour cherry juice (Prunus cerasus).
Changes in the activities of semicarbazide-sensitive amine oxidase in inferior mesenteric artery segments and in serum of patients with type 2 diabetes.
Cytotoxic, Antioxidant, and Enzyme Inhibitory Properties of the Traditional Medicinal Plant Matthiola incana (L.) R. Br.
Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy.
Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride.
Evaluation of the inhibition of monoamine oxidase A by bioactive coffee compounds protecting serotonin degradation.
Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus.
Islet-specific monoamine oxidase A and B expression depends on MafA transcriptional activity and is compromised in type 2 diabetes.
Monoamine oxidase and semicarbazide-sensitive amine oxidase kinetic analysis in mesenteric arteries of patients with type 2 diabetes.
Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 activity exerts an antidiabetic action in Goto-Kakizaki rats.
Diabetic Angiopathies
Prolonged treatment with aminoguanidine strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats.
Diabetic Cardiomyopathies
Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: Implications in heart failure.
Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy.
Diabetic Foot
Linezolid-Associated Serotonin Syndrome. A Report of Two Cases.
Diabetic Nephropathies
Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy.
The protective effect of losartan in the nephropathy of the diabetic rat includes the control of monoamine oxidase type A activity.
Diabetic Retinopathy
Soluble Vascular Adhesion Protein-1 Mediates Spermine Oxidation as Semicarbazide-Sensitive Amine Oxidase: Possible Role in Proliferative Diabetic Retinopathy.
[Determination of serum semicarbazide-sensitive amine oxidase activity in diabetic retinopathy in type-2 diabetes]
Disorders of Excessive Somnolence
Pharmacologic safety concerns in Parkinson's disease: facts and insights.
Selegiline reduces daytime sleepiness in patients with Parkinson's disease.
Disseminated Intravascular Coagulation
Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.
Down Syndrome
Diminished activity of platelet monoamine oxidase in Down's syndrome.
Mitochondrial enzyme deficiencies in Down's syndrome.
Platelet monoamine oxidase activity in Down's syndrome.
Drug-Related Side Effects and Adverse Reactions
Adverse drug reaction following treatment with monoamine oxidase inhibitors and imipramine and similar drugs: report of two cases--one successfully treated with chlorpromazine.
Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.
Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.
Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.
The medical consequences of the selection of an antidepressant.
[Adverse drug reactions in combined treatment with tricyclic antidepressants and monoamine oxidase inhibitors]
Duodenal Ulcer
A study of the effects of monoamine oxidase inhibitors on the experimental gastric and duodenal ulcers.
Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
Effect of furazolidone on gut catecholamine in cysteamine-induced duodenal ulcer in the rat.
Evidence for the involvement of dopamine agonists and antagonists in duodenal ulcer disease.
MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and norepinephrine, but not dopamine.
Dysautonomia, Familial
Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia.
Dyskinesias
A biochemical study of tardive dyskinesia in young male patients.
Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.
Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Garcinol, a multifaceted sword for the treatment of Parkinson's disease.
Influence of Single Nucleotide Polymorphisms in COMT , MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease.
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Monoamine oxidase B inhibitors for early Parkinson's disease.
Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease.
Parkinson disease: an update.
Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors.
Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease.
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia.
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
The pharmacology of Parkinson's disease: basic aspects and recent advances.
The therapy of the motor symptoms in the advanced stage of Parkinson's disease.
Treatment of levodopa-induced motor complications.
[Medical and surgical treatment of Parkinson's disease].
Dystonia
Catechol-O-methyltransferase activity in cultured human skin fibroblasts from controls and patients with dystonia musculorum deformans.
Eclampsia
Drug therapy of hypertensive crises.
Hypertensive emergencies. Etiology and management.
Encephalomyelitis
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE).
Encephalomyelitis, Autoimmune, Experimental
Monoamine oxidase and acetylcholinesterase activity in animals with experimental allergic encephalomyelitis.
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE).
[ Serotonin and monoamine oxidase activity in the dynamics of experimental neuroallergy]
[Change in monoamine content and monoamine oxidase activity in brain structures during experimental allergic encephalomyelitis]
End Stage Liver Disease
Hepatic encephalopathy: An update of pathophysiologic mechanisms.
Endometrial Neoplasms
miR-522 facilitates the prosperities of endometrial carcinoma cells by directly binding to monoamine oxidase B.
Epilepsies, Partial
Abstracts of the 5th joint meeting of the german, austrian, and swiss sections of the international league against epilepsy basle, may 16-19, 2007.
Epilepsy
Bupropion SR for smoking cessation.
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Epilepsy and Serotonin (5HT): Variations of 5HT Related Genes in Temporal Lobe Epilepsy.
Flumazenil and seizures: analysis of 43 cases.
Higher transcription alleles of the MAOA-uVNTR polymorphism are associated with higher seizure frequency in temporal lobe epilepsy.
Human monoamine oxidase. Lack of brain and platelet correlation.
Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.
Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
L-deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice.
Monoamine oxidase activity in blood platelets of migraine patients.
Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: imaging in volunteers and patients with temporal lobe epilepsy.
Monoamine oxidases A and B gene polymorphisms in migraine patients.
New directions in monoamine oxidase A and B selective inhibitors and substrates.
Platelet monoamine oxidase activity in epilepsy.
Safinamide (Newron Pharmaceuticals).
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl--analysis of kinetic data.
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.
Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
[ELECTROENCEPHALOGRAPHIC CONTRIBUTION TO THE STUDY OF MONOAMINE OXIDASE INHIBITING DRUGS: CHANGES INDUCED IN EXPERIMENTAL EPILEPSY IN RABBITS.]
Epilepsy, Generalized
Association analysis between a regulatory-promoter polymorphism of the human monoamine oxidase A gene and idiopathic generalized epilepsy.
Epilepsy, Reflex
[Change in the catalytic properties of mitochondrial monoamine oxidase in experimental audiogenic epilepsy]
Epilepsy, Temporal Lobe
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Epilepsy and Serotonin (5HT): Variations of 5HT Related Genes in Temporal Lobe Epilepsy.
Higher transcription alleles of the MAOA-uVNTR polymorphism are associated with higher seizure frequency in temporal lobe epilepsy.
Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: imaging in volunteers and patients with temporal lobe epilepsy.
Erectile Dysfunction
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction.
Moringa oleifera leaf and seed inclusive diets influenced the restoration of biochemicals associated with erectile dysfunction in the penile tissue of STZ-induced diabetic male rats treated with/without Acarbose drug.
Naringin regulates erectile dysfunction by abolition of apoptosis and inflammation through NOS/cGMP/PKG signalling pathway on exposure to Bisphenol-A in hypertensive rat model.
Three cases of female anorgasmia associated with MAOIs.
Esophageal Neoplasms
Decreased monoamine oxidase (MAO) activity and MAO-A expression as diagnostic indicators of human esophageal cancers.
Essential Hypertension
Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension.
Exfoliation Syndrome
Lysyl oxidase-like protein 1 (LOXL1) gene polymorphisms and exfoliation glaucoma in a Central European population.
Familial Primary Pulmonary Hypertension
MAO-A promoter polymorphism and idiopathic pulmonary arterial hypertension.
Fatigue Syndrome, Chronic
A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome.
Fibromyalgia
Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A.
Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome.
MONOAMINE OXIDASE INHIBITORS (MAOIs) FOR FIBROMYALGIA SYNDROME.
Protective Effect of Esculetin, Natural Coumarin in Mice Model of Fibromyalgia: Targeting Pro-Inflammatory Cytokines and MAO-A.
The association between fibromyalgia and polymorphism of monoamine oxidase A and interleukin-4.
Which genotype of MAO gene that the patients have are likely to be most susceptible to the symptoms of fibromyalgia?
Fragile X Syndrome
Testing for association of the monoamine oxidase A promoter polymorphism with brain structure volumes in both autism and the fragile X syndrome.
Frontotemporal Dementia
Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide.
[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia.
Galactorrhea
[Treatment of extra-puerperal galactorrhea with the MAO-B inhibitor selegiline]
Ganglion Cysts
The novel phytocomponent asiaticoside-D isolated from Centella asiatica exhibits monoamine oxidase-B inhibiting potential in the rotenone degenerated cerebral ganglions of Lumbricus terrestris.
Gastritis
[Intravital histopathological changes in the gastric mucosa and the activity of certain cytoplasmic enzymes (cholinesterase, monoamine oxidase, histaminase) and acetylcholine in peptic ulcer and chronic gastritis]
Gastritis, Atrophic
Enzyme activities in human gastric mucosa in gastritis and resected stomachs.
Gastroesophageal Reflux
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Genetic Diseases, Inborn
Anesthetic management in MAO-A and MAO-B deficiency: a case report.
Use of a monoclonal antibody for comparative studies of monoamine oxidase B in mitochondrial extracts of human brain and peripheral tissues.
Glaucoma
Drug-induced secondary glaucoma.
Human platelet monoamine oxidase activity in glaucoma.
Identification of pathogenic genes and transcription factors in glaucoma.
Ocular hypotensive effects of monoamine oxidase-A inhibitors in rabbit.
[Changes of monoamine oxidase (MAO) activity in patients with glaucoma (author's transl)]
[Monoamine oxidase activity in women with glaucoma]
Glaucoma, Angle-Closure
3. Phenylephrine hydrochloride.
Drug-induced secondary glaucoma.
Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults.
[Drug-induced glaucoma].
Glioblastoma
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.
Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1.
Monoamine oxidase B activity is increased in human gliomas.
Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case.
PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma.
Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study.
Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.
The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment.
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
[Development of experimental brain tumors in modulated amine metabolism]
Glioma
Antioxidant defense against antidepressants in C6 and 1321N1 cells.
Assessment of DNA damage in C6 glioma cells after antidepressant treatment using an alkaline comet assay.
Densities of I2-imidazoline receptors, imidazoline receptor proteins, and MAO-B sites in human gliomas and pituitary adenomas.
Design and Synthesis of a MAO-B-Selectively Activated Prodrug Based on MPTP: A Mitochondria-Targeting Chemotherapeutic Agent for Treatment of Human Malignant Gliomas.
Differences in the structures of monoamine oxidases A and B in rat clonal cell lines.
Expression of A and B types of monoamine oxidase in differentiated neuroblastoma hybrid cells.
Expression of A and B types of monoamine oxidase in neuroblastoma hybrid cells.
Expression of differentiated activities in reaggregated brain cell cultures.
Glioma cell antioxidant capacity relative to reactive oxygen species produced by dopamine.
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Increase of survival of dopaminergic neuroblastoma in co-cultures with C-6 glioma by R-(-)-deprenyl.
Inflammation and inducible nitric oxide synthase have no effect on monoamine oxidase activity in glioma cells.
Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro.
Metabolism of biogenic amines in neuroblastoma and glioma cells in culture.
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Monoamine oxidase B activity is increased in human gliomas.
Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1? and with transcription factors Sp1 and Sp3.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Near-Infrared Monoamine Oxidase Inhibitor Biodistribution in a Glioma Mouse Model.
PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma.
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Rational Design of a Two-Photon Fluorogenic Probe for Visualizing Monoamine Oxidase?A Activity in Human Glioma Tissues.
Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells.
The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment.
[Effect of monoamine oxidase inhibitor on the differentiation of malignant glioma cell].
Glomerulonephritis
Drug therapy of hypertensive crises.
Glomerulonephritis, IGA
Monoamine oxidase inhibitors for IgA nephropathy.
Glucose Intolerance
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Goiter
Dissociation of thyrotropin-dependent enzyme activities, reduced iodide transport, and preserved iodide organification in nonfunctioning thyroid adenoma and multinodular goiter.
[Acetylcholine and monoamine oxidase content of blood serum in patients with toxic goiter]
[Monoamine oxidase activity in diffuse toxic goiter and primary hypothyroidism]
Gout
Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress.
Monoamine oxidase A gene polymorphisms and enzyme activity associated with risk of gout in Taiwan aborigines.
Granuloma Annulare
Increased activity of serum amine oxidases in granuloma annulare, necrobiosis lipoidica and diabetes.
Graves Disease
Monoamine oxidase (MAO) activity and its forms in normal and pathological human thyroid tissues.
Gynecomastia
[Gynecomastia induced by a monoamine oxidase inhibitor]
Hallucinations
(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Ayahuasca: Uses, Phytochemical and Biological Activities.
Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features.
Reduced platelet monoamine oxidase activity in a subgroup of schizophrenic patients.
THE EFFECT OF D-LYSERGIC ACID DIETHYLAMIDE TARTRATE (LSD-25) AND D-2-BROMO LYSERGIC ACID TARTRATE (BOL-148) ON SPECIFIC CHOLINESTERASE AND MONOAMINE OXIDASE OF RAT LIVER AS POSSIBLE FACTORS IN THE MECHANISM OF HALLUCINATION. A HISTOCHEMICAL STUDY.
THE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE TARTRATE (LSD-25) ON THE CHOLINESTERASES AND MONOAMINE OXIDASE IN THE SPINAL CORD: A POSSIBLE FACTOR IN THE MECHANISM OF HALLUCINATION.
Withdrawal phenomena associated with antidepressant and antipsychotic agents.
Head Injuries, Closed
Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.
Headache Disorders
Prophylactic pharmacological treatment of chronic daily headache.
The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Heart Arrest
Could monoamine oxidase inhibitors promote asystole in electroconvulsive therapy patients?
Inhibition of monoamine oxidase A increases recovery after experimental cardiac arrest.
Heart Diseases
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction.
Cardiac disorders and antidepressant medications.
Histochemically demonstrable monoamine oxidase activity in the adult human heart in various cardiac diseases.
Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet.
Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts.
Monoamine oxidase-A, serotonin and norepinephrine: synergistic players in cardiac physiology and pathology.
Monoamine Oxidases, Oxidative Stress, and Altered Mitochondrial Dynamics in Cardiac Ageing.
Safe use of epinephrine with halothane anesthesia.
Serum monoamine oxidase in the heart diseases.
Heart Failure
ABNORMALITIES OF SERUM MONOAMINE OXIDASE IN CHRONIC CONGESTIVE HEART FAILURE.
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Cardiac catechol O-methyltransferase and monoamine oxidase activity in congestive heart failure.
Effect of ibopamine and the active metabolite epinine on the catecholamine content of rat hypothalamus and brainstem in vitro.
Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: Implications in heart failure.
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Major depression and heart failure: Interest of monoamine oxidase inhibitors.
Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload.
Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts.
Monoamine Oxidase Is Overactivated in Left and Right Ventricles from Ischemic Hearts: An Intriguing Therapeutic Target.
Oxidative stress by monoamine oxidase-A impairs transcription factor-EB activation and autophagosome clearance leading to cardiomyocyte necrosis and heart failure.
p53-PGC-1? Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice.
Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure.
Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure.
Practical considerations for the treatment of elderly patients with migraine.
Production of a truncated soluble human semicarbazide-sensitive amine oxidase mediated by a GST-fusion protein secreted from HEK293 cells.
Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2.
Semicarbazide-sensitive amine oxidase and mortality in chronic heart failure.
Hemiplegia
[RECURRING LEFT HEMIPLEGIA SECONDARY TO A MEDICAMENTOUS ORTHOSTATIC HYPOTENSION CAUSED BY A MONOAMINE OXIDASE INHIBITOR IN A PATIENT WITH STENOSIS OF THE INTERNAL CAROTID AT ITS ORIGIN. CURE BY ENDARTERIECTOMY AND CESSATION OF THE MAOI.]
Hemochromatosis
Isoenzyme composition of human plasma monoamine oxidase in normal subjects and in fibrotic liver disease.
Hemorrhagic Fever with Renal Syndrome
[Inactivation of serotonin in patients with hemorrhagic fever with kidney syndrome]
Hepatic Encephalopathy
Analysis of the effect of the polyprenol preparation ropren and the choline alphoscerate preparation gliatilin on the membrane-bound and soluble forms of cholinesterases and monoamine oxidase of rat brain and serum in the tetrachloromethane model system of hepatic encephalopathy.
Hepatic encephalopathy: An update of pathophysiologic mechanisms.
Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy.
Hepatitis
Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B.
The diagnostic potential of the combined determination of serum monoamine oxidase and N-acetyl-beta-D-glucosaminidase for fibroproliferative liver diseases.
[Prognostic value of monoamine oxidase (MAO) in the serum in correlation to the activity of AspAt and AlAt in viral hepatitis]
[Serum monoamine oxidase (MAO) as a prognostic indicator in chronic active hepatitis. II]
Hepatitis, Chronic
[Preliminary results of the studies of serum monoamine oxidase and ceruloplasmin activities in patients with chronic hepatitis and liver cirrhosis]
[Serum monoamine oxidase (MAO) as a prognostic indicator in chronic active hepatitis. II]
Herpes Zoster
Histochemical localization of monoamine oxidase types A and B in the adrenal gland.
Identification of imidazoline-receptor binding sites in cortex and medulla of the bovine adrenal gland. Colocalization with MAO-A and MAO-B.
In vivo voltammetric monitoring of noradrenaline release and catecholamine metabolism in the hypothalamic paraventricular nucleus.
Hirschsprung Disease
Cholinesterases and monoamine oxidase in congenital megacolon.
Histiocytoma, Malignant Fibrous
Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer.
HIV Infections
Elevated brain monoamine oxidase activity in SIV and HIV neurological disease.
Hodgkin Disease
Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Huntington Disease
Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls.
Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.
Intra- and extraneuronal monoamineoxidase-A and -B activities after central axotomy (hemisection) on rats.
Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion.
Platelet monoamine oxidase activity in Huntington's chorea.
Platelet monoamine oxidase activity in patients with Huntington's disease.
Platelet monoamine oxidase activity in subjects tested for Huntington's disease gene mutation.
Treatment of depression in Huntington's disease with monoamine oxidase inhibitors.
Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.
[Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals (author's transl)]
Hydrocephalus
Acute hydrocephalus upregulates monoamine oxidase mRNA in neonatal rat brain.
Hyperalgesia
CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Fisetin exerts antihyperalgesic effect in a mouse model of neuropathic pain: engagement of spinal serotonergic system.
Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.
Hypercholesterolemia
Influence of experimental hypercholesterolemia on the monoamine oxidase activity in rabbit arteries.
Hyperemia
Changes in the plethysmogram patterns of finger reactive hyperemia in nutritional (alcoholic) liver disease patients with increased serum monoamine oxidase activities.
Hyperglycemia
Effect of experimental diabetes on the catecholamine metabolism in rat brain.
Treatment of depression in patients with diabetes mellitus.
Hyperinsulinism
Plasma semicarbazide-sensitive amine oxidase is moderately decreased by pronounced exogenous hyperinsulinemia but is not associated with insulin sensitivity and body fat.
Hyperkalemia
Peaked "T" waves with tranylcypromine (parnate) overdose.
Hyperkinesis
Locomotor stimulation by L-dopa: relative importance of noradrenaline receptor activation.
Hyperlipidemias
Hyperlipidemia Downregulate Brain Antioxidant Defense Enzymes and Neurotrophins in Rats: Assessment of the Modulatory Potential of EPA+DHA and Zerumbone.
Hyperlipoproteinemias
Chiral inversion of drugs: coincidence or principle?
Hyperparathyroidism, Secondary
Effect of chronic renal failure with and without secondary hyperparathyroidism on the activities of synaptosomal tyrosine hydroxylase and monoamine oxidase.
Hyperprolactinemia
Pharmacological causes of hyperprolactinemia.
Hypersensitivity
Abstracts of the 5th joint meeting of the german, austrian, and swiss sections of the international league against epilepsy basle, may 16-19, 2007.
Bupropion SR for smoking cessation.
Iproclozide fulminant hepatitis. Possible role of enzyme induction.
Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.
Vascular hypersensitivity and potentiation of catecholamines induced by monoamine oxidase inhibition.
[Dynamics of the activity of mitochondrial monoamine oxidase of the liver in allergic reactions of the direct type]
[Role of monoamine oxidase inhibition in the formation of delayed-type hypersensitivity]
Hypertension
"Ping-pong" gaze in severe monoamine oxidase inhibitor toxicity.
A case of MAO inhibitor/MDMA interaction: agony after ecstasy.
A method for measurement of monoamine oxidase inhibition in man: application to studies on hypertension.
Acute myocarditis after massive phenelzine overdose.
Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study.
Aromatic L-amino acid decarboxylase, dopamine beta-hydroxylase, monoamine oxidase, malondialdehyde, and acid phosphatase in rat brain capillaries and kidney glomeruli in experimental hypertension.
Brain and vascular monoamine oxidase activity in the deoxycorticosterone-salt hypertensive rat.
Cardiac hypertrophy in spontaneously hypertensive rats.
Clinical and pharmacologic observations on a monoamine oxidase inhibitor (pargyline hydrochloride) in hypertension.
CLINICAL EXPERIENCE WITH THE MONOAMINE OXIDASE INHIBITOR, DL-SERINE-N-ISOPROPYLHYDRAZIDE (RO 4-1038), IN THE TREATMENT OF HYPERTENSION.
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Drug-induced hypertension. Recognition and management in older patients.
Evaluation of 2 monoamine oxidase inhibitors (iproniazid and JB 516) in the therapy of arterial hypertension.
Hemodynamics and monoamine oxidase activity in spontaneously hypertensive rats (SHR).
Hypertension during anaesthesia with monoamine oxidase inhibitors.
HYPERTENSION WITH MONOAMINE OXIDASE INHIBITORS.
Hypertensive emergencies. Etiology and management.
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
MAO-A promoter polymorphism and idiopathic pulmonary arterial hypertension.
Monoamine oxidase defect in essential arterial hypertension. A single dose pargyline test.
Monoamine oxidase inhibitors in hypertension.
Monoamine oxidase inhibitors in hypertension: preliminary observations on nialamide.
Perioperative management of drug therapy, clinical considerations.
Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs.
Proceedings: Monoamine oxidase defect in essential arterial hypertension: 'a single dose pargyline test'.
Safe use of epinephrine with halothane anesthesia.
Safety and tolerability of linezolid.
Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults.
Systemic reactions to ophthalmic drug preparations.
The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.
The use of monoamine oxidase inhibitors as adjuncts in the treatment of hypertension and angina pectoris.
Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines.
Tyramine and irreversible monoamine oxidase inhibitors in clinical practice.
[5 years treatment of arterial hypertension with a monoamine oxidase inhibiter (Marsilid)]
[ACUTE HYPERTENSION DUE TO MONOAMINE OXIDASE INHIBITORS AND THE EATING OF CHEESE.]
[Ambulatory treatment of hypertension with a monoamine oxidase inhibitor]
[Antidepressive agents and hypertension: A case/no-case study in French pharmacovigilance database].
[Arterial hypertension in chronic bronchial obstruction and various problems of its treatment]
[Blood phenolsulfotransferase and monoamine oxidase-B activity in essential arterial hypertension]
[Clinical experiences with monoamine oxidase inhibitor (niamid) in the treatment of hypertension.]
[Disorder of monoamine oxidase activity in essential arterial hypertension]
[Effect of several drugs on hypertension and cerebral monoamine oxidase activity in old rats exposed to environmental stress]
[Hemodynamics, serotonin and monoamine oxidase in bronchial asthma and systemic arterial hypertension]
[Monoamine oxidase activity in rheumatic heart disease associated with symptomatic hypertension]
[Monoamine oxidase and essential arterial hypertension]
[Myocardial status, hemodynamics and pressor humoral substances in patients with bronchial asthma and arterial hypertension]
[On the treatment of arterial hypertension with a drug inhibiting monoamine oxidase (DL-serine-N2-isopropylhydrazide).]
[Results obtained with a new monoamine oxidase inhibitor in the treatment of arterial hypertension.]
[Studies on mode of action of monoamine oxidase inhibitors on the experimental hypertension of the rat]
[Treatment of certain refractory arterial hypertensions with a monoamine oxidase inhibitor]
Hypertension, Malignant
Hypertensive emergencies. Etiology and management.
Hypertension, Portal
Cardiovascular responses to serotonin in experimental liver disease.
Serum monoamine oxidase (MAO) levels in portal hypertension.
Hypertension, Pregnancy-Induced
Dopamine in the Pathophysiology of Preeclampsia and Gestational Hypertension: Monoamine Oxidase (MAO) and Catechol-O-methyl Transferase (COMT) as Possible Mechanisms.
Hypertension, Renovascular
Drug therapy of hypertensive crises.
Hypertensive Encephalopathy
Hypertensive emergencies. Etiology and management.
Posterior Reversible Encephalopathy Syndrome Secondary to Hypertensive Encephalopathy Brought on by a MAO Inhibitor: A Case Report.
Hyperthyroidism
Biogenic amines and thyrotoxicosis.
Effect of hyper- and hypothyroidism on platelet monoamine oxidase activity and serotonin metabolism.
Influence of hypo- and hyperthyroidism on noradrenaline metabolism in brown adipose tissue of the developing rat.
Influence of neonatal and adult hyperthyroidism on behavior and biosynthetic capacity for norepinephrine, dopamine and 5-hydroxytryptamine in rat brain.
Metabolism of monoamines and diamines in hyperthyroid and hypothyroid rats.
The activities of antioxidant enzymes and monoamine oxidase and uncoupling protein 1 content in brown fat of hypo- and hyperthyroid rats.
Hypertrophy, Left Ventricular
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Hypoglycemia
Effect of experimental diabetes on the catecholamine metabolism in rat brain.
Treatment of depression in patients with diabetes mellitus.
Weight gain with antidepressants and lithium.
Hypokinesia
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Future directions in the treatment of Parkinson's disease.
Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells.
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Hyponatremia
Medically serious adverse effects of newer antidepressants.
Hypophosphatemia, Familial
Role of Chronic Inhibition of Dopamine-Metabolizing Enzymes in the Regulation of Renal Sodium and Phosphate Excretion in the Rat Remnant Kidney.
Hypotension
2-bromoethylamine, a suicide inhibitor of semicarbazide-sensitive amine oxidase, increases hydralazine hypotension in rats.
Biochemical and physiological effects of chlordimeform.
Blood pressure effects of monoamine oxidase inhibitors--the highs and lows.
Catecholamines and monoamine oxidase activity in turkeys with high or low blood pressure.
Controlling monoamine oxidase inhibitor hypotension with 9-alpha-fluoro-hydrocortisone.
Enhancement of hydralazine hypotension by low doses of isoniazid. Possible role of semicarbazide-sensitive amine oxidase inhibition.
Hypotension following use of monoamine oxidase inhibitor.
MAO inhibitors and coronary artery surgery: a patient death.
Phenelzine toxicity responsive to dantrolene.
Practical considerations for the treatment of elderly patients with migraine.
Semicarbazide-sensitive amine oxidase substrates potentiate hydralazine hypotension: possible role of hydrogen peroxide.
[Pharmacological aspect of the treatment of hypotension induced by phenothiazine neuroleptics and monoamine oxidase inhibitors]
Hypotension, Orthostatic
Acute psychosis following phenelzine discontinuation.
Antidepressants and falls in the elderly.
Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness.
Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure.
Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
Drug-induced orthostatic hypotension.
Evaluating dysfunction of the autonomic nervous system.
Idiopathic orthostatic hypotension controlled with a monoamine oxidase inhibitor and 9-alpha-fluorohydrocortisone.
Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.
Recent advances in geriatric psychopharmacology.
St. John's wort: a new alternative for depression?
Systemic reactions to ophthalmic drug preparations.
The cardiovascular effects of antidepressants.
The use of newer antidepressants for panic disorder.
Tranylcypromine compared with L-deprenyl in Alzheimer's disease.
Treatment of Depression in Patients with Concomitant Cardiac Disease.
Treatment of neurogenic orthostatic hypotension with a monoamine oxidase inhibitor and tyramine.
[Hypertension en orthostatic hypotension during use of monoamine oxidase (MAO) inhibitors].
[RECURRING LEFT HEMIPLEGIA SECONDARY TO A MEDICAMENTOUS ORTHOSTATIC HYPOTENSION CAUSED BY A MONOAMINE OXIDASE INHIBITOR IN A PATIENT WITH STENOSIS OF THE INTERNAL CAROTID AT ITS ORIGIN. CURE BY ENDARTERIECTOMY AND CESSATION OF THE MAOI.]
[Treatment of neurogenic orthostatic hypotension by an association of tyramine and a monoamine oxidase inhibitor (author's transl)]
Hypothyroidism
Effect of hyper- and hypothyroidism on platelet monoamine oxidase activity and serotonin metabolism.
Presence of kynurenine hydroxylase in developing rat brain.
Selective effects of neonatal hypothyroidism on monoamine oxidase activities in the rat brain.
[Monoamine oxidase activity in diffuse toxic goiter and primary hypothyroidism]
[The effect of hyper- and hypothyroidism on serotonin and noradrenaline concentration and monoamine oxidase activity in the nerve endings of the brains of rats]
Illusions
Correlation between platelet monoamine oxidase activity and the strength of a visual illusion.
Infarction, Middle Cerebral Artery
Lack of protection from ischemic injury of monoamine oxidase B-deficient mice following middle cerebral artery occlusion.
Infections
Aberrations in cerebral vascular functions due to Plasmodium yoelii nigeriensis infection in mice.
Alteration of free radical metabolism in the brain of mice infected with scrapie agent.
Brugia malayi: status of host during different stages of infection.
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
Linezolid-Associated Serotonin Syndrome. A Report of Two Cases.
Monoamine oxidase inhibition and CNS immunodeficiency infection.
Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity.
Patient selection in ambulatory anesthesia - an evidence-based review: part II.
Serum enzyme tests in hepatosplenic schistosomiasis.
The response of histamine degrading enzymes to nematode infection.
Toxicity of derivatives from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine against Toxoplasma gondii after infection of differentiated 3T3-L1 cells.
Tryptamine and sakuranetin accumulation in Sekiguchi lesions associated with the light-enhanced resistance of the lesion mimic mutant of rice to Magnaporthe oryzae
[Monoamine oxidase (MAO) activity in the blood and homogenates of the spleen, mesenteric lymph node and small intestine of mice with experimental Trichinella spiralis infection]
[Monoamine oxidase (MAO) activity in the blood, spleen, mesenteric lymph node and small intestine of mice with Trichinella pseudospiralis infection]
[Separate and combined action of antibiotics and vitamins on monoamine oxidase activity of the rabbit liver in staphylococcal infection]
Infectious Mononucleosis
Studies of platelet monoamine oxidase activity in Epstein-Barr and dengue virus infections.
Infertility
The effect of R-(-)-deprenyl administration on reproductive parameters of rat males.
[Monoamine oxidase activity in women treated with clomide for functional sterility]
Influenza, Human
Amantadine as augmentation therapy in the management of treatment-resistant depression.
Presence of specific antigen and alterations in enzyme activity in the chorio-allantoic membrane of embryonate hen eggs infected with influenza A2 or B virus.
Insulin Resistance
A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid ''Harmine''.
Plasma semicarbazide-sensitive amine oxidase is moderately decreased by pronounced exogenous hyperinsulinemia but is not associated with insulin sensitivity and body fat.
Insulinoma
Comparison of monoamine oxidase in golden hamster islets and insulinoma.
Monoamine oxidase and catechol-O-methyltransferase activity in hamster and rat insulinomas.
Intellectual Disability
A new look at the promoter of the human monoamine oxidase A gene: mapping transcription initiation sites and capacity to drive luciferase expression.
Association of monoamine oxidase A and serotonin transporter gene functional variants with intellectual disability related behavioral problems.
Catecholamine metabolism and psychiatric or behavioral disorders.
Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis.
Monoamine oxidase activity of blood platelets and their ability to store 5-hydroxytryptamine in some mental deficiencies.
Relationship between monoamine oxidase (MAO) A specific activity and proportion of human skin fibroblasts which express the enzyme in culture.
Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes.
The promoter of the human monoamine oxidase A gene.
[Discovery of monoamine oxidase forms A and B]
Intracranial Aneurysm
Association between semicarbazide-sensitive amine oxidase, a regulator of the glucose transporter, and elastic lamellae thinning during experimental cerebral aneurysm development: laboratory investigation.
Intracranial Arteriosclerosis
[MONOAMINE OXIDASE INHIBITORS IN PSYCHOSES DUE TO CEREBRAL ARTERIOSCLEROSIS.]
Intracranial Hemorrhages
Hypertensive emergencies. Etiology and management.
Iron Deficiencies
Fetal iron deficiency and genotype influence emotionality in infant rhesus monkeys.
Influence of prenatal iron deficiency and MAOA genotype on response to social challenge in rhesus monkey infants.
Iron deficiency in the rat: biochemical studies of brain metabolism.
Prenatal iron deficiency and monoamine oxidase A (MAOA) polymorphisms: combined risk for later cognitive performance in rhesus monkeys.
[Characterization of rat monoamine oxidase and the alteration of their activities in iron deficiency]
Irritable Bowel Syndrome
Correlation of serotonin and monoamine oxidase levels with anxiety level in diarrhea-predominant irritable bowel syndrome.
Ischemic Stroke
Change in platelet monoamine oxidase activity in the acutest period of ischemic stroke is associated with the degree of neurological recovery.
Mass spectrometry-based urinary metabolomics for the investigation on the mechanism of action of Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. leaves against ischemic stroke in rats.
[Role of semicarbazide-sensitive amine oxidase in disturbances of endogenic detoxication in ischemic stroke patients].
Joint Diseases
[Monoamine oxidase activity in the synovial fluid in joint diseases]
Kidney Diseases
Semicarbazide-sensitive amine oxidase and kidney disease.
Kidney Failure, Chronic
Alteration of serum semicarbazide-sensitive amine oxidase activity in chronic renal failure.
Effect of chronic renal failure with and without secondary hyperparathyroidism on the activities of synaptosomal tyrosine hydroxylase and monoamine oxidase.
Identification, expression and tissue distribution of a renalase homologue from mouse.
[Monoamine oxidase activity in patients with chronic renal failure and in experimental uremia in rats]
Kidney Neoplasms
Monoamine Oxidase B in Renal Cell Carcinoma.
Learning Disabilities
[Genetic polymorphism of COMT in mental disorders]
Leprosy
Chiral inversion of drugs: coincidence or principle?
Lesch-Nyhan Syndrome
Monoamine oxidase activity decreased in cells lacking hypoxanthine phosphoribosyltransferase activity.
Monoamine oxidase and catechol-o-methyltransferase activity in cultured fibroblasts from patients with maple syrup urine disease, Lesch-Nyhan syndrome and healthy controls.
Leukemia
An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW-2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteins.
Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.
Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells.
[The vehaviour of monoaminooxydase (MAO) activity in tumours. I. MAO activity measurement in experimental tumours (author's transl)]
Leukoencephalopathies
Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders.
Leukoencephalopathy, Progressive Multifocal
Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders.
Leukopenia
A case report of leukopenia associated with phenelzine.
Lewy Body Disease
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
The neuroprotective mechanism of action of the multimodal drug ladostigil.
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
Lichen Planus
Measurement of Serum Monoamine Oxidase in Lichen Planus and its Clinical Significance.
Lipoma
Prediction of cell type-specific gene modules: identification and initial characterization of a core set of smooth muscle-specific genes.
Liver Cirrhosis
Bupropion SR for smoking cessation.
Rapid Two-Photon Fluorescence Imaging of Monoamine Oxidase B for Diagnosis of Early-Stage Liver Fibrosis in Mice.
Validity of monoamine oxidase in serum for diagnosis of liver cirrhosis: estimation of predictive values, sensitivities and specificities.
[Determination of serum monoamine oxidase (MAO) --diagnosis of liver fibrosis]
[Preliminary results of the studies of serum monoamine oxidase and ceruloplasmin activities in patients with chronic hepatitis and liver cirrhosis]
Liver Diseases
Abnormalities of serum monoamine oxidase in chronic liver disease.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Association of gene polymorphisms encoding dopaminergic system components and platelet MAO-B activity with alcohol dependence and alcohol dependence-related phenotypes.
Changes in the plethysmogram patterns of finger reactive hyperemia in nutritional (alcoholic) liver disease patients with increased serum monoamine oxidase activities.
Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease.
Clinical study of serum monoamine oxidase in liver diseases. Colorimetric method with p-benzylamino-azo-beta-naphthol as substrate.
Comparative studies on human plasma monoamine oxidase in normal subjects and in fibrotic liver disease.
Isoenzyme composition of human plasma monoamine oxidase in normal subjects and in fibrotic liver disease.
Mitochondrial-Targeted and Near-Infrared Fluorescence Probe for Bioimaging and Evaluating Monoamine Oxidase A Activity in Hepatic Fibrosis.
Monoamine oxidase activity and kinetic properties in platelet-rich plasma from controls, chronic alcoholics, and patients with nonalcoholic liver disease.
Quantitative evaluation of brain edema by radionuclide imaging technique.
The diagnostic potential of the combined determination of serum monoamine oxidase and N-acetyl-beta-D-glucosaminidase for fibroproliferative liver diseases.
Validity of monoamine oxidase in serum for diagnosis of liver cirrhosis: estimation of predictive values, sensitivities and specificities.
[Serum monoamine oxidase (MAO) in the differential diagnosis of chronic liver disease. I]
[Serum monoamine oxidase activity in liver diseases]
Liver Neoplasms, Experimental
Association of monoamine oxidase with lipid--a comparative study mitochondria from Novikoff hepatoma and rat liver.
Lordosis
Effects of monoamine oxidase inhibition on female sexual behavior, serotonin levels and type A and B monoamine oxidase activity.
Inhibition of lordosis behavior by intrahypothalamic implants of pargyline.
Pargyline-induced increase in serotonin levels: correlation with inhibition of lordosis in rats.
Lung Injury
Xanthine oxidase-induced lung injury inhibits removal of 5-hydroxytryptamine from the pulmonary circulation.
Lung Neoplasms
Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.
Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Novel 4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains: design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis and tumor cell.
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Repurposing of a monoamine oxidase A inhibitor?heptamethine carbocyanine dye conjugate for paclitaxel?resistant non?small cell lung cancer.
Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients.
The role of monoamine oxidase A in HPV-16 E7-induced epithelial-mesenchymal transition and HIF-1? protein accumulation in non-small cell lung cancer cells.
[Serum monoamine oxidase activity and serotoninopectic properties in lung cancer patients]
Lymphadenopathy
Lymphadenopathy associated with monoamine oxidase inhibitors.
Lymphoma
[Effect of Monoamine Oxidase Inhibitor Phenelzine on Proliferation of Mantle Cell Lymphoma and Its Mechanism].
Lymphoma, Mantle-Cell
[Effect of Monoamine Oxidase Inhibitor Phenelzine on Proliferation of Mantle Cell Lymphoma and Its Mechanism].
Macular Edema
Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema.
Malaria
Topological polar surface area: a useful descriptor in 2D-QSAR.
Malnutrition
Effects of nutritional stress on brain tyramine concentration and dopamine turnover.
Maintenance of central and peripheral monoamine oxidase activity in developing rats subjected to disturbed alimentary rhythms and undernutrition.
Mania
Acute psychosis following phenelzine discontinuation.
Antidepressant-associated mania: a controlled comparison with spontaneous mania.
Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis.
Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials.
Clinical herbal interactions with conventional drugs: from molecules to maladies.
Drug-induced mania.
Implications of monoamine oxidase inhibitor-induced hypomania.
Managing bipolar depression.
Mania after withdrawal of isocarboxazid.
Mania associated with high percentage of inhibition of monoamine oxidase.
Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor.
Platelet monoamine oxidase activity and clomipramine-induced mania in unipolar depressed patients.
Platelet serotonin and serum lipids in psychotic mania.
Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features.
Two cases of hypomania following the addition of L-tryptophan to a monoamine oxidase inhibitor.
Maple Syrup Urine Disease
Monoamine oxidase and catechol-o-methyltransferase activity in cultured fibroblasts from patients with maple syrup urine disease, Lesch-Nyhan syndrome and healthy controls.
Massive Hepatic Necrosis
Iproclozide fulminant hepatitis. Possible role of enzyme induction.
[Fatal fulminant hepatitis in 2 women taking toloxatone (Humoryl)]
Melanoma
Cudarflavone B provides neuroprotection against glutamate-induced mouse hippocampal HT22 cell damage through the Nrf2 and PI3K/Akt signaling pathways.
Current status of symptomatic medical therapy in Parkinson's disease.
The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
Memory Disorders
Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil.
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Extract of Yi Zhi Fang improves learning and memory behaviours of mice and its possible mechanisms.
Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats.
Positive Modulation of Pink Nelumbo nucifera Flowers on Memory Impairment, Brain Damage, and Biochemical Profiles in Restraint Rats.
Meningioma
Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl.
Monoamine oxidase B activity is increased in human gliomas.
Menkes Kinky Hair Syndrome
[Histochemical and biochemical investigations of monoamine oxidase activity level in the brain of the brindled mouse]
Methemoglobinemia
Serotonin syndrome after cardiopulmonary bypass: a case demonstrating the interaction between methylene blue and selective serotonin reuptake inhibitors.
Migraine Disorders
A close look at fenfluramine and dexfenfluramine.
A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach.
A study of the activity of platelet monoamine oxidase in patients with migraine headaches or with 'cluster headaches'.
Anti-migraine and anti-depression activities of Tianshu capsule by mediating Monoamine oxidase.
Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine.
Association Between Polymorphisms of DRD2, COMT, DBH, and MAO-A Genes and Migraine Susceptibility: A Meta-Analysis.
Changes in monoamine oxidase (MAO) activity in migraine.
Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression.
Enterococci in milk and milk products.
Human platelet monoamine oxidase activity in health and disease: a review.
Implications of the platelet monoamine oxidase deficit during migraine attacks.
Investigation of some biological trait markers in migraine: deuterated tyramine challenge test, monoamine oxidase, phenolsulfotransferase and plasma and urinary biogenic amine and acid metabolite levels.
Kinetics and thermolability of platelet monoamine oxidase in cluster headache and migraine.
Letter: Monoamine oxidase and migraine.
MAO activity, serotonin metabolism and aggregation of platelets from migraine patients. A preliminary study.
MAOA, MTHFR, and TNF-? genes polymorphisms and personality traits in the pathogenesis of migraine.
Migraine and cluster headache: links between platelet monoamine oxidase activity, smoking and personality.
Migraine and depression: biological aspects.
Migraine headache: epidemiologic perspectives.
Monoamine oxidase activities in patients with migraine or with cluster headache during the acute phases and after treatment with L-5-hydroxytryptophan.
Monoamine oxidase activity in blood platelets of migraine patients.
Monoamine oxidase inhibition in the treatment of migraine.
Monoamine oxidase inhibitors in the control of migraine.
Monoamine oxidases A and B gene polymorphisms in migraine patients.
New Frontiers in Selective Human MAO-B Inhibitors.
Platelet monoamine oxidase activity and headache.
Platelet monoamine oxidase activity in female migraine patients.
Platelet monoamine oxidase in migraine.
Platelet serotonin measures in migraine.
Platelet size: no correlation with migraine or monoamine oxidase activity.
Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
Selegeline, a MAO B inhibitor, is not effective in the prophylaxis of migraine without aura--an open study.
Serotonin metabolism in migraine.
The potential effectiveness of moclobemide, the new monoamine oxidase inhibitor, in the prophylaxis of migraine.
Transitory platelet monoamine oxidase deficit in migraine: some reflections.
Urinary output of endogenous monoamine oxidase inhibitor and isatin during acute migraine attacks.
[Severe migraine, monoamine oxidase inhibitors and methysergide.]
Migraine with Aura
Monoamine oxidases A and B gene polymorphisms in migraine patients.
Platelet monoamine oxidase activity and headache.
Migraine without Aura
Monoamine oxidases A and B gene polymorphisms in migraine patients.
monoamine oxidase deficiency
Altered behavior and alcohol tolerance in transgenic mice lacking MAO A: a comparison with effects of MAO A inhibitor clorgyline.
Anesthetic management in MAO-A and MAO-B deficiency: a case report.
Are MAO-A deficiency states in the general population and in putative high-risk populations highly uncommon?
Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the iNTD registry.
Behavioral Disinhibition and Reduced Anxiety-like Behaviors in Monoamine Oxidase B-Deficient Mice.
Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.
Cataplexy and monoamine oxidase deficiency in Norrie disease.
CSF acid monoamine metabolites in psychotic syndromes: what might they signify?
Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements.
Early postnatal inhibition of serotonin synthesis results in long-term reductions of perseverative behaviors, but not aggression, in MAO A-deficient mice.
Effect of MAO A deficiency on different kinds of aggression and social investigation in mice.
From aggression to autism: new perspectives on the behavioral sequelae of monoamine oxidase deficiency.
Hepatic monoamine oxidase deficiency in Reye syndrome.
Migraine headache: epidemiologic perspectives.
Mild learning difficulties and offending behaviour--is there a link with monoamine oxidase A deficiency?
Monoamine oxidase A deficiency: biogenic amine metabolites in random urine samples.
Monoamine Oxidase Deficiency Causes Prostate Atrophy and Reduces Prostate Progenitor Cell Activity.
Monoamine oxidase deficiency in males with an X chromosome deletion.
Monoamine oxidase deficiency: a cause of flushing and attention-deficit/ hyperactivity disorder?
Monoamine oxidase deficiency: a cause of symptomatic hyperserotoninemia in the absence of carcinoid.
Monoaminergic control of vasopressin and VIP expression in the mouse suprachiasmatic nucleus.
Novel monoamine oxidase A knock out mice with human-like spontaneous mutation.
Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.
Relationship between monoamine oxidase (MAO) A specific activity and proportion of human skin fibroblasts which express the enzyme in culture.
Screen for MAOA mutations in target human groups.
Social Deficits and Perseverative Behaviors, but not Overt Aggression, in MAO-A Hypomorphic Mice.
Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes.
The aggression and behavioral abnormalities associated with monoamine oxidase A deficiency are rescued by acute inhibition of serotonin reuptake.
Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia.
[Characteristics of behavior of knockout mice with genetic monoamine oxidase A deficiency]
[Development of serotonergic neurons of dorsal raphe nuclei in mice with knockout of monoamine oxidase A and 5-HT1A and 5-HT1B autoreceptor]
Motor Neuron Disease
Medical Management of Frontotemporal Dementias: The Importance of the Caregiver in Symptom Assessment and Guidance of Treatment Strategies.
Monoamine oxidase (MAO), 5-hydroxyindole acetic acid (5 HIAA) and homovanillic acid (HVA) in motor neuron disease.
Neurotransmitter abnormalities in patients with motor neuron disease.
Movement Disorders
A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study.
The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.
MPTP Poisoning
1-Methyl-4-phenylpyridinium (MPP+) binds with high affinity to a beta-carboline binding site located on monoamine oxidase type A in rat brain.
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and norepinephrine, but not dopamine.
Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.
The hypothalamus in MPTP-induced parkinsonism.
Multiple Sclerosis
Platelet monoamine oxidase and plasma dopamine-beta-hydroxylase activities in patients with multiple sclerosis.
Multiple System Atrophy
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients.
Muscle Hypotonia
Autonomic nervous system function in narcolepsy.
De novo microdeletion of Xp11.3 exclusively encompassing the monoamine oxidase A and B genes in a male infant with episodic hypotonia: A genomics approach to personalized medicine.
Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements.
Muscle Rigidity
Anaesthesia in elderly patients with neurodegenerative disorders: special considerations.
Phenelzine toxicity responsive to dantrolene.
[Acute toloxatone poisoning. Apropos of 122 cases]
Muscular Diseases
Catecholamine-induced muscle weakness.
Monoamine oxidase inhibition prevents mitochondrial dysfunction and apoptosis in myoblasts from patients with collagen VI myopathies.
Overexpression of semicarbazide-sensitive amine oxidase in human myopathies.
Muscular Dystrophies
Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD Patients.
[Adrenergic structures and monoamine oxidase activity in dystrophic skeletal muscles]
Muscular Dystrophy, Duchenne
Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD Patients.
Turner syndrome and Xp deletions: clinical and molecular studies in 47 patients.
[Mitochondrial monoamine oxidase in progressive Duchenne muscular dystrophy]
Mutism
Phenomenology and treatment of selective mutism.
The use of medication in selective mutism: a systematic review.
Myasthenia Gravis
Platelet monoamine oxidase-B activity in Parkinson's disease.
Mycoses
[The histamine-serotonin-monoamine oxidase system in patients with foot mycosis during treatment]
Mydriasis
Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Myocardial Infarction
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Cardiomyocytes-specific deletion of monoamine oxidase B reduces irreversible myocardial ischemia/reperfusion injury.
Ectopic ventricular rhythms and myocardial infarction in the domestic pig and their response to nialamide, a monoamine oxidase inhibitor.
Histochemical studies of monoamine oxidase in experimental myocardial infarctions.
[Biogenic amines (catecholamines, serotonin) in the blood and serum monoamine oxidase activity in acute myocardial infarct and some of its complications]
[Clinical studies on the changes of serum monoamine oxidase activities in myocardial infarction (author's transl)]
[Role of lysosomes in experimental myocardial infarct lesions and in protecte action of monoamine oxidase inhitors]
[Thrombocyte functional resistance and histamine and serotonin metabolism in ischemic heart disease]
Myocarditis
[Changes in the monoamine oxidase activity in experimental myocarditis and arthritis in rats thymectomized at birth]
[Changes in the monoamine oxidase activity of neonatally thymectomized rats with experimental myocarditis and arthritis]
Myoclonus
Beneficial effects of serotonin precursors in postanoxic action myoclonus.
Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?
Myoclonus in the rat induced by p,p'-DDT and the role of altered monoamine function.
Observations on chloralose-induced myoclonus in guinea-pigs.
Tryptamine-induced myoclonus in guinea-pigs pretreated with a monoamine oxidase inhibitor indicates pre- and post-synaptic actions of tryptamine upon central indoleamine systems.
Narcolepsy
Analysis of the monoamine oxidase genes and the Norrie disease gene locus in narcolepsy.
MAO-A and COMT polymorphisms and gene effects in narcolepsy.
Selegiline in narcolepsy.
Selegiline in the treatment of narcolepsy.
Treatment of intractable narcolepsy with a monoamine oxidase inhibitor.
Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine-a pilot study.
Nasopharyngeal Carcinoma
Monoamine oxidase A is down-regulated in EBV-associated nasopharyngeal carcinoma.
Necrobiosis Lipoidica
Increased activity of serum amine oxidases in granuloma annulare, necrobiosis lipoidica and diabetes.
Neoplasm Metastasis
Elevated activity of semicarbazide-sensitive amine oxidase in blood from patients with skeletal metastases of prostate cancer.
Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.
MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.
Monoamine Oxidase A is a Major Mediator of Mitochondrial Homeostasis and Glycolysis in Gastric Cancer Progression.
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling.
Monoamine oxidase-A targeting probe for prostate cancer imaging and inhibition of metastasis.
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.
Repurposing antitubercular agent isoniazid for treatment of prostate cancer.
Site-specific expression of amine oxidases in breast cancer metastases.
Neoplasms
A comparison of cell proliferation in normal and neoplastic intestinal epithelia following either biogenic amine depletion or monoamine oxidase inhibition.
A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
Amine oxidase activities in chemically-induced mammary cancer in the rat.
Amine oxidase activities in rat breast cancer induced experimentally with 7,12-dimethylbenz(alpha)anthracene.
An indicator of cancer: downregulation of Monoamine Oxidase-A in multiple organs and species.
An integrated approach for identifying priority contaminant in the Great Lakes Basin - Investigations in the Lower Green Bay/Fox River and Milwaukee Estuary areas of concern.
Aspartic acid substitutions in monoamine oxidase-A reveal both catalytic-dependent and -independent influences on cell viability and proliferation.
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.
Biochemical and ultrastructural differences between muco-epidermoid and carcinoid tumors of the bronchus.
Biochemical composition of edge and center of malignant hamster insulinoma.
Biochemical studies on mitochondria isolated from Normal and Neoplastic Tissues of the Mouse Mammary Gland.
Biodistribution and radiation dosimetry of 11C-harmine in baboons.
Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways.
Clinical contraindications to allergen immunotherapy: an EAACI position paper.
Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma.
Conjugation with polyamines enhances the antitumor activity of naphthoquinones against human glioblastoma cells.
Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A.
Decreased monoamine oxidase (MAO) activity and MAO-A expression as diagnostic indicators of human esophageal cancers.
Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine.
Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
Distribution of cyclic 3',5'-phosphodiesterase, monoamine oxidase & beta-glucuronidase in liver tumours induced by technical grade hexachlorocyclohexane in inbred swiss mice.
Dopa-decarboxylase and monoamine oxidase activities in a transplantable islet cell tumor of the golden hamster.
Drug therapy of hypertensive crises.
Dual inhibitors of LSD1 and spermine oxidase.
Effect of metastatic cancer on platelet monoamine oxidase activity and serotonin metabolism.
Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells.
Effects of various synthetic retinoids on proliferation and immunophenotype of human melanoma cells in vitro.
Enzyme inhibition of dopamine metabolism alters 6-[18 F]FDOPA uptake in orthotopic pancreatic adenocarcinoma.
Exploration of phytochemicals for inhibition of monoamine oxidase-A induced cancer using molecular docking studies.
Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes.
Histochemical observations of monoamine oxidase activity in human tumors.
Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer.
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain.
Increased 3-nitrotyrosine levels in mitochondrial membranes and impaired respiratory chain activity in brain regions of adult female rats submitted to daily vitamin A supplementation for 2 months.
Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo.
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells.
Inhibitor structure-guided design and synthesis of near-infrared fluorescent probes for monoamine oxidase A (MAO-A) and its application in living cells and in vivo.
Isoform selectivity of harmine-conjugated 1,2,3-triazoles against human monoamine oxidase.
L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.
Loxl2 is dispensable for dermal development, homeostasis and tumour stroma formation.
MAOA and TNF-? gene polymorphisms are associated with photophobia but not osmophobia in patients with migraine.
MAOA, MTHFR, and TNF-? genes polymorphisms and personality traits in the pathogenesis of migraine.
Mental adaptation to cancer: depression and blood platelet monoamine oxidase activity in breast cancer patients.
Metabolism and storage of catecholamines in rats with pheochromocytoma implants.
Mitochondrial-Targeted and Near-Infrared Fluorescence Probe for Bioimaging and Evaluating Monoamine Oxidase A Activity in Hepatic Fibrosis.
Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer.
Monoamine and diamine oxidase activity in the diagnosis of carcinoid tumors.
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Monoamine oxidase a inhibitor-near-infrared dye conjugate reduces prostate tumor growth.
Monoamine Oxidase A is a Major Mediator of Mitochondrial Homeostasis and Glycolysis in Gastric Cancer Progression.
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Monoamine oxidase activity in Ehrlich ascites tumor.
Monoamine oxidase B activity is increased in human gliomas.
Monoamine Oxidase B in Renal Cell Carcinoma.
Monoamine oxidase B inhibitor enhances experimental carcinogenesis in rat colon induced by azoxymethane.
Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1? and with transcription factors Sp1 and Sp3.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.
Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction.
Novel 4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains: design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis and tumor cell.
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Platelet monoamine oxidase and phenolsulphotransferase M and P in cancer.
Positron emission tomography in acromegaly and other pituitary adenoma patients.
Prevention of Mammary Tumor Development through Neuroimmunomodulation in the Spleen and Lymph Nodes of Old Female Sprague-Dawley Rats by L-Deprenyl.
Prophylactic neuroprotective efficiency of co-administration of Ginkgo biloba and Trifolium pretense against sodium arsenite-induced neurotoxicity and dementia in different regions of brain and spinal cord of rats.
Psychiatric morbidity and platelet monoamine oxidase activity in cancer patients.
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity.
Regulation of semicarbazide-sensitive amine oxidase expression by tumor necrosis factor-alpha in adipocytes: functional consequences on glucose transport.
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.
Resorufin Enters the Photodynamic Therapy Arena: A Monoamine Oxidase Activatable Agent for Selective Cytotoxicity.
Role of Plant-Derived Flavonoids and Their Mechanism in Attenuation of Alzheimer's and Parkinson's Diseases: An Update of Recent Data.
Secretory, enzymatic, and morphological characterization of rat pancreatic endocrine tumours induced by streptozotocin and nicotinamide.
Selenazolyl-hydrazones as Novel Selective MAO Inhibitors With Antiproliferative and Antioxidant Activities: Experimental and In-silico Studies.
Serum vascular adhesion protein-1 level is higher in smokers than non-smokers.
Single nucleotide polymorphisms in obesity-related genes and all-cause and cause-specific mortality: a prospective cohort study.
Synthesis and biological evaluation of 2-phenoxyacetamide analogues, a novel class of potent and selective monoamine oxidase inhibitors.
Targeting monoamine oxidase A for T cell-based cancer immunotherapy.
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.
The effects of vitamin A supplementation for 3 months on adult rat nigrostriatal axis: Increased monoamine oxidase enzyme activity, mitochondrial redox dysfunction, increased ?-amyloid(1-40) peptide and TNF-? contents, and susceptibility of mitochondria to an in vitro H(2)O(2) challenge.
The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
The neurotoxicity of ?-amyloid peptide toward rat brain is associated with enhanced oxidative stress, inflammation and apoptosis, all of which can be attenuated by scutellarin.
The significance of monoamine oxidase-A expression in high grade prostate cancer.
Topological polar surface area: a useful descriptor in 2D-QSAR.
Type B monoamine oxidase activity in human brain malignant tumors.
Using Molecular Docking Analysis to Discovery Dregea sinensis Hemsl. Potential Mechanism of Anticancer, Antidepression, and Immunoregulation.
[Comparative study of the effect of inhibitors of monoamine oxidase and ftorafur on the growth of de-differentiated astrocytoma]
[Development of experimental brain tumors in modulated amine metabolism]
[Effect of flavonoids from Sophora flavescens in aging mice induced by D-galactos].
[Effects of berberine on learning and memory ability in vascular cognitive impairment rats].
[Histochemical studies on the monoamine oxidase activity of human neoplasms. (Preliminary note)]
[Monoamine oxidase activity in tumors of the neural crest]
[Monoamine oxidase activity of cell nuclei from the liver of mice with transplanted malignant neoplasms]
[Monoamine oxidase and diamine oxidase activities in patients with primary bronchial cancer]
[Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells]
[The modification of the catalytic activity of mitochondrial monoaminoxidase and the suppression of the growth of experimental brain tumors]
[The vehaviour of monoaminooxydase (MAO) activity in tumours. I. MAO activity measurement in experimental tumours (author's transl)]
Nervous System Diseases
An update on amine oxidase inhibitors: Multifaceted drugs.
Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease.
Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
Characterization of Three Extracellular ?-Glucosidases Produced by a Fungal Isolate Aspergillus sp. YDJ14 and Their Hydrolyzing Activity for a Flavone Glycoside.
Clinical applications of MAO-inhibitors.
Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane.
Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and reversible inhibitors of human monoamine oxidase B.
Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors.
Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
Effect of neurocatin on the activity of monoamine oxidase B in rat brain synaptosomes.
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.
Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders.
Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders.
Hybrid caffeic acid derivatives as monoamine oxidases inhibitors: synthesis, radical scavenging activity, molecular docking studies and in silico ADMET analysis.
In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid.
Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.
Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.
Iron-Restricted Diet Affects Brain Ferritin Levels, Dopamine Metabolism and Cellular Prion Protein in a Region-Specific Manner.
Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid.
Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study.
MAO inhibitory activity of 2-arylbenzofurans versus 3-arylcoumarins: synthesis, in vitro study, and docking calculations.
Metal- and Solvent-Free Multicomponent Decarboxylative A3-Coupling for the Synthesis of Propargylamines: Experimental, Computational, and Biological Investigations.
Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme.
Monoamine oxidase inhibitors, their structural analogues, and neuroprotection.
Myoclonic seizures after abrupt withdrawal from phenelzine and alprazolam.
Perspectives on MAO-B in aging and neurological disease: where do we go from here?
Piperazine multi-substituted triarylphosphine oxide compound as an instant "light-up" fluorescent probe for monoamine oxidase.
Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders.
Platelet monoamine oxidase activity is related to MAOB intron 13 genotype.
Radiosynthesis and in vivo evaluation of [11C]-labelled pyrrole-2-carboxamide derivates as novel radioligands for PET imaging of monoamine oxidase A.
Recent Updates on Pyrazolines Derivatives as Promising Candidates for Neuropsychiartic and Neurodegenerative disorders.
Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171/Gln206 and conserved water molecules in the active site cavity.
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition.
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Sensitive and Selective Ratiometric Fluorescence Probes for Detection of Intracellular Endogenous Monoamine Oxidase A.
Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.
Structural Exploration of Synthetic Chromones as Selective MAO-B Inhibitors: A Mini Review.
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders.
Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors.
Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.
Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents.
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.
The role of monoamine oxidase enzymes in the pathophysiology of neurological disorders.
Upregulation of serotonin transporter by alcohol in human dendritic cells: possible implication in neuroimmune deregulation.
What a Difference a Methyl Group Makes: The Selectivity of Monoamine Oxidase?B Towards Histamine and N-Methylhistamine.
Neuralgia
5-HT1A receptor-mediated attenuation of heat hyperalgesia and mechanical allodynia by chrysin in mice with experimental mononeuropathy.
CHF 3381.
CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain.
Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice.
Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects.
Moclobemide in chronic neuropathic pain: preliminary case reports.
Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.
The antinociceptive effect of reversible monoamine oxidase-A inhibitors in a mouse neuropathic pain model.
Neuritis
[Toxic neuritis caused by monoamine oxidase inhibitors]
Neurobehavioral Manifestations
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.
Neuroblastoma
A link between monoamine oxidase-A and apoptosis in serum deprived human SH-SY5Y neuroblastoma cells.
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.
Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro.
Assignment of genes for human monoamine oxidases A and B to the X chromosome.
Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat.
Beta-Blockers and Berberine: A Possible Dual Approach to Contrast Neuroblastoma Growth and Progression.
Biotransformation of the MPTP analog trans-1-methyl-4-[4-dimethylaminophenylethenyl]-1,2,3,6-tetra- hydropyridine to a fluorescent pyridinium metabolite by intact neuroblastoma cells.
Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons.
Cellular uptake of quercetin and luteolin and their effects on monoamine oxidase-A in human neuroblastoma SH-SY5Y cells.
Effect of riboflavin on monoamine oxidase activity in cultured neuroblastoma cells.
Estrogen modulation of catecholamine synthesis and monoamine oxidase A activity in the human neuroblastoma cell line SK-ER3.
Estrogenic control of monoamine oxidase A activity in human neuroblastoma cells expressing physiological concentrations of estrogen receptor.
Expression of A and B types of monoamine oxidase in differentiated neuroblastoma hybrid cells.
Expression of A and B types of monoamine oxidase in neuroblastoma hybrid cells.
Expression of differentiated activities in reaggregated brain cell cultures.
Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1.
Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/?-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.
Increase of survival of dopaminergic neuroblastoma in co-cultures with C-6 glioma by R-(-)-deprenyl.
Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
Inhibition of monoamine oxidase activity by repetitive transcranial magnetic stimulation: implications for inter-train interval and frequency.
Iron modulates the activity of monoamine oxidase B in SH-SY5Y cells.
Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells.
L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells.
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
Measurement of mitochondrial respiration in permeabilized murine neuroblastoma (N-2alpha) cells, a simple and rapid in situ assay to investigate mitochondrial toxins.
Metabolism of biogenic amines in neuroblastoma and glioma cells in culture.
Monoamine oxidase A variants are associated with heavy betel quid use.
Monoamine oxidase activity decreased in cells lacking hypoxanthine phosphoribosyltransferase activity.
Monoamine oxidase-A knockdown in human neuroblastoma cells reveals protection against mitochondrial toxins.
Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells.
Monoamine oxidase-A promotes protective autophagy in human SH-SY5Y neuroblastoma cells through Bcl-2 phosphorylation.
Monoamine Oxidase-B Inhibition Facilitates ?-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.
Parkin suppresses the expression of monoamine oxidases.
Properties of monoamine oxidase in mouse neuroblastoma N1E-115 cells.
R1, a novel repressor of the human monoamine oxidase A.
Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
Resorufin Enters the Photodynamic Therapy Arena: A Monoamine Oxidase Activatable Agent for Selective Cytotoxicity.
Retinoic acid activates monoamine oxidase B promoter in human neuronal cells.
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
The human testis-determining factor SRY localizes in midbrain dopamine neurons and regulates multiple components of catecholamine synthesis and metabolism.
The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.
Thyroid hormone binding and regulation of adrenergic enzymes in two neuroblastoma cell lines.
Toxicity of MPTP and structural analogs in clonal cell lines of neuronal origin expressing B type monoamine oxidase activity.
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells.
Tyrosine hydroxylase and monoamine oxidase-A activity increases in differentiating human neuroblastoma after elimination of dividing cells.
Neurodegenerative Diseases
''70th Birthday Professor Riederer'' Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?
(-)-Deprenyl fails to promote axonal regeneration of retinal ganglion cells in vitro and in vivo.
(Hetero-)(arylidene)arylhydrazides as Multitarget-Directed Monoamine Oxidase Inhibitors.
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors.
3D-QSAR and in-silico studies of natural products and related derivatives as monoamine oxidase inhibitors.
4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis.
A rational approach to elucidate human monoamine oxidase molecular selectivity.
A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression.
Activation of monoamine oxidase type-B by aluminum in rat brain homogenate.
Age-related behavioral phenotype of an astrocytic monoamine oxidase-B transgenic mouse model of Parkinson's disease.
An update on amine oxidase inhibitors: Multifaceted drugs.
Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase.
Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors.
Association of monoamine oxidase B alleles with age at onset in amyotrophic lateral sclerosis.
Bacopa monnieri and L-deprenyl differentially enhance the activities of antioxidant enzymes and the expression of tyrosine hydroxylase and nerve growth factor via ERK 1/2 and NF-?B pathways in the spleen of female wistar rats.
Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.
Benextramine and derivatives as novel human monoamine oxidases inhibitors: an integrated approach.
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Binding models of reversible inhibitors to type-B monoamine oxidase.
Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.
Bromophenols from Symphyocladia latiuscula Target Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases.
Chemical characterization of small-molecule inhibitors of monoamine oxidase B synthesized from the Acanthopanax senticosus root with affinity ultrafiltration mass spectrometry.
Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases.
Click-Reaction-Triggered SERS Signals for Specific Detection of Monoamine Oxidase B Activity.
Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies.
Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.
Deciphering the detailed structure-activity relationship of coumarins as Monoamine oxidase enzyme inhibitors-An updated review.
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Design, Synthesis, and Biological Evaluation of Pyridazinones Containing the (2-Fluorophenyl) Piperazine Moiety as Selective MAO-B Inhibitors.
Development of 2D, 3D-QSAR and Pharmacophore Modeling of Chalcones for the Inhibition of Monoamine Oxidase B.
Differential increases in catecholamine metabolizing enzymes in amyotrophic lateral sclerosis.
Discovery of two new classes of potent monoamine oxidase-B inhibitors by tricky chemistry.
Docking of Natural Products against Neurodegenerative Diseases: General Concepts.
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO.
Emodin Derivatives as Multi-Target-Directed Ligands Inhibiting Monoamine Oxidase and Antagonizing Vasopressin V1A Receptors.
Exploration of a Library of 3,4-(Methylenedioxy)aniline-Derived Semicarbazones as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase: Design, Synthesis, and Evaluation.
Exploration of Umbelliferone Based Derivatives as Potent MAO Inhibitors: Dry vs. Wet Lab Evaluation.
Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells.
Glyceraldehyde-3-Phosphate Dehydrogenase-Monoamine Oxidase B-Mediated Cell Death-Induced by Ethanol is Prevented by Rasagiline and 1-R-Aminoindan.
High throughput Screening to Identify Natural Human Monoamine Oxidase B Inhibitors.
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening.
In silico identification of novel and selective monoamine oxidase B inhibitors.
In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases.
In vitro anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida).
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
Indole Alkaloids And Semisynthetic Indole Derivatives As Multifunctional Scaffolds Aiming The Inhibition Of Enzymes Related To Neurodegenerative Diseases - A Focus On Psychotria L. Genus.
Indole alkaloids of Psychotria as multifunctional cholinesterases and monoamine oxidases inhibitors.
Inflammation and inducible nitric oxide synthase have no effect on monoamine oxidase activity in glioma cells.
Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl.
Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants.
Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines.
Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
Integrated Binary QSAR-Driven Virtual Screening and In Vitro Studies for Finding Novel hMAO-B-Selective Inhibitors.
Investigation of pyrazolo[1,5-a]quinoxalin-4-ones as novel monoamine oxidase inhibitors.
Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.
Iododerivative of pargyline: a potential tracer for the exploration of monoamine oxidase sites by SPECT.
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.
Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration.
Ligand based screening of chemical constituents from African medicinal plants for the identification of MAOB inhibitors.
Link between monoamine oxidase and nitric oxide.
Longitudinal changes in 18 F-THK5351 positron emission tomography in corticobasal syndrome.
M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
Maintenance therapies for late-life recurrent major depression: research and review circa 1995.
MAO inhibitors and their wider applications: a patent review.
Marine natural products with monoamine oxidase (MAO) inhibitory activity.
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor.
Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.
Monoamine oxidase (MAO) inhibitory activity: 3-phenylcoumarins versus 4-hydroxy-3-phenylcoumarins.
Monoamine oxidase and agitation in psychiatric patients.
Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes.
Monoamine oxidase inhibition by selected dye compounds.
Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography.
Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.
Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
Multi-target, Neuroprotective and Neurorestorative M30 Improves Cognitive Impairment and Reduces Alzheimer's-Like Neuropathology and Age-Related Alterations in Mice.
Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.
Multiscale Modeling of Two-Photon Probes for Parkinson's Diagnostics Based on Monoamine Oxidase B Biomarker.
Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3 R Antagonism for Neurodegenerative Diseases.
Natural based piperine derivatives as potent monoamine oxidase inhibitors: an in silico ADMET analysis and molecular docking studies.
Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines; new MAO-B inhibitors without amphetamine-like properties.
Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and ?-amyloid in aging and Alzheimer's disease.
Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against A?(1-42)-induced toxicity.
Neuroprotective Potential of Verbascoside Isolated from Acanthus mollis L. Leaves through Its Enzymatic Inhibition and Free Radical Scavenging Ability.
New indane derivatives containing 2-hydrazinothiazole as potential acetylcholinesterase and monoamine oxidase-B inhibitors.
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Novel Diels-Alder Type Adducts from Morus alba Root Bark Targeting Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases.
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B.
On the functions of monoamine oxidase, the emotions, and adaptation to stress.
Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders.
Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO?B inhibitors.
Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B.
Pharmacophore-Based 3D-QSAR Analysis of Thienyl Chalcones as a New Class of Human MAO-B Inhibitors: Investigation of Combined Quantum Chemical and Molecular Dynamics Approach.
Plant secondary metabolites- potent inhibitors of monoamine oxidase isoforms.
Potent and Selective Monoamine Oxidase-B Inhibitory Activity: Fluoro- vs. Trifluoromethyl-4-hydroxylated Chalcone Derivatives.
Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
Promising selective MAO-B inhibition by sesamin, a lignan from Zanthoxylum flavum stems.
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
Pyrazoline-based mycobactin analogues as MAO-inhibitors.
Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders.
Quinolinyl-Thienyl Chalcones as Monoamine Oxidase Inhibitors and their In Silico Modeling Studies.
Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Rasagiline improves learning and memory in young healthy rats.
Ratiometric Near-Infrared Fluorescent Probe for Synergistic Detection of Monoamine Oxidase B and Its Contribution to Oxidative Stress in Cell and Mice Aging Models.
Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Recent Updates on Pyrazolines Derivatives as Promising Candidates for Neuropsychiartic and Neurodegenerative disorders.
Revealing the role of fluorine pharmacophore in chalcone scaffold for shifting the MAO-B selectivity: investigation of a detailed molecular dynamics and quantum chemical study.
Selected chromone derivatives as inhibitors of monoamine oxidase.
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana).
Selective MAO-B inhibitors: a lesson from natural products.
Selenazolyl-hydrazones as Novel Selective MAO Inhibitors With Antiproliferative and Antioxidant Activities: Experimental and In-silico Studies.
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Single heterocyclic compounds as Monoamine Oxidase Inhibitors: From past to present.
Symmetrical aryl linked bis-iminothiazolidinones as new chemical entities for the inhibition of monoamine oxidases: Synthesis, in vitro biological evaluation and molecular modelling analysis.
Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B.
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Synthesis and Evaluation of 2-benzylidene-1-tetralone Derivatives for Monoamine Oxidase Inhibitory Activity.
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors.
Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl--analysis of kinetic data.
The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase.
The MAO Inhibitor Tranylcypromine Alters LPS- and A?-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD.
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
The perspective of caffeine and caffeine derived compounds in therapy.
The use of chemometrics to study multifunctional indole alkaloids from Psychotria nemorosa (Palicourea comb. nov.). Part II: Indication of peaks related to the inhibition of butyrylcholinesterase and monoamine oxidase-A.
The Use of Multiscale Molecular Simulations in Understanding a Relationship between the Structure and Function of Biological Systems of the Brain: The Application to Monoamine Oxidase Enzymes.
Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders.
Type a and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells.
Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release.
Neurodermatitis
A follow-up study on the chemotherapy of neurodermatitis with a monoamine oxidase inhibitor.
On the treatment of neurodermatitis with a monoamine oxidase inhibitor. The chemotherapy of psychosomatic illness through A-REM suppression.
Neuroendocrine Tumors
Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.
Neuroinflammatory Diseases
(E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) Phenol Ameliorates MPTP-Induced Dopaminergic Neurodegeneration by Inhibiting the STAT3 Pathway.
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque.
Attenuation of Ischemic Stroke-Caused Brain Injury by a Monoamine Oxidase Inhibitor Involves Improved Proteostasis and Reduced Neuroinflammation.
Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
Elevated brain monoamine oxidase activity in SIV and HIV neurological disease.
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO.
In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity.
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and ?-amyloid in aging and Alzheimer's disease.
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Preclinical Evaluation of TSPO and MAO-B PET Radiotracers in an LPS Model of Neuroinflammation.
Recurrent Lobar Hemorrhages and Multiple Cortical Superficial Siderosis in a Patient of Alzheimer's Disease With Homozygous APOE ?2 Allele Presenting Hypobetalipoproteinemia and Pathological Findings of 18F-THK5351 Positron Emission Tomography: A Case Report.
The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6.
The MAO Inhibitor Tranylcypromine Alters LPS- and A?-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD.
Neuromuscular Diseases
Early changes of muscle mitochondria in Duchenne dystrophy. Partition and activity of mitochondrial enzymes in fractionated muscle of unaffected boys and adults and patients.
Non-alcoholic Fatty Liver Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Nutrition Disorders
[ADJUNCTION OF A MONOAMINE OXIDASE INHIBITOR TO CLASSIC TREATMENTS OF DISEASES OF THE DIGESTIVE TRACT AND NUTRITION DISORDERS.]
Obesity
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Cytotoxic, Antioxidant, and Enzyme Inhibitory Properties of the Traditional Medicinal Plant Matthiola incana (L.) R. Br.
Family-based association study between the monoamine oxidase A gene and obesity: implications for psychopharmacogenetic studies.
Hypoxia inhibits semicarbazide-sensitive amine oxidase activity in adipocytes.
Personality and illness: Genetic connections?
Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats.
Two functional serotonin polymorphisms moderate the effect of food reinforcement on BMI.
Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.
[Effect of different dietary programs on serum monoamine oxidase activity in patients with obesity]
[Monoamine oxidase activity of the blood in metabolic-alimentary obesity]
[Serum monoamine oxidase activity in alimentary obesity]
Obesity, Abdominal
Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and the activity of semicarbazide-sensitive amine oxidase.
Obesity, Morbid
Patient selection in ambulatory anesthesia - an evidence-based review: part II.
Obstetric Labor, Premature
Changes in serum calcium, magnesium, cyclic AMP and monoamine oxidase levels during pregnancy and under prolonged ritodrine treatment for preterm labor.
Optic Neuritis
[Bilateral optic neuritis with sudden onset occurring in an atherosclerotic subject, a heavy smoker, poisoned by an monoamine oxidase inhibitor (MAOI)]
[Optic neuritis caused by monoamine oxidase inhibitors]
Osteoarthritis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Chondrocytic monoamine oxidase activity in the development of natural murine osteoarthritis.
Tryptophan metabolism in the joint diseases.
Osteogenesis Imperfecta
Influence of age, sex and osteogenesis imperfecta on count, protein content, and monoamine oxidase activity of human thrombocytes.
Overweight
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Attenuation of Weight Gain and Prevention of Associated Pathologies by Inhibiting SSAO.
Pancreatic Neoplasms
11C-harmine as a potential PET tracer for ductal pancreas cancer: in vitro studies.
Paralysis
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Central serotonin receptor sensitivity in rats with experimental allergic encephalomyelitis.
Jasonia glutinosa (L.) DC., a Traditional Herbal Tea, Exerts Antioxidant and Neuroprotective Properties in Different In Vitro and In Vivo Systems.
Monoamine oxidase inhibitory activities of indolylalkaloid toxins from the venom of the colonial spider Parawixia bistriata: functional characterization of PwTX-I.
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy.
Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal.
Viola cornuta and Viola x wittrockiana: Phenolic compounds, antioxidant and neuroprotective activities on Caenorhabditis elegans.
Parkinson Disease
'Bad guys' among the antiparkinsonian drugs.
(-)-Deprenyl fails to promote axonal regeneration of retinal ganglion cells in vitro and in vivo.
(-)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats.
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
1-N-substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: synthesis and evaluation as MAO inhibitors.
1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors.
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
3-Arylcoumarins as highly potent and selective monoamine oxidase B inhibitors: Which chemical features matter?
3-Coumaranone derivatives as inhibitors of monoamine oxidase.
? Safinamide for Parkinson's disease.
?-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group.
A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group.
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease.
A meta-analysis on relationship of MAOB intron 13 polymorphisms, interactions with smoking/COMT H158L polymorphisms with the risk of PD.
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
A rapid thin-layer chromatography bioautographic method for detecting the monoamine oxidase inhibitors in plants.
A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
A scaffold hopping approach to identify novel monoamine oxidase B inhibitors.
A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models.
Activation of monoamine oxidase type-B by aluminum in rat brain homogenate.
Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice.
Adjuvant potential of selegiline in treating acute toxicity of aluminium phosphide in rats.
Advances in the pharmacologic management of early Parkinson disease.
Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.
Age-related behavioral phenotype of an astrocytic monoamine oxidase-B transgenic mouse model of Parkinson's disease.
Age-related memory decline and longevity under treatment with selegiline.
Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson's disease.
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced ?-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson's Disease.
Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
An allelic association study of monoamine oxidase B in Parkinson's disease.
An expert opinion on safinamide in Parkinson's disease.
An inducible MAO-B mouse model of Parkinson's disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics.
An integrated approach to patient management in Parkinson's disease.
An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease.
An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
An update on amine oxidase inhibitors: Multifaceted drugs.
An update on pharmacological approaches to neurodegenerative diseases.
Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP(+)-treated SH-SY5Y human dopaminergic cells.
Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase.
Antioxidant therapy in Parkinson's disease.
Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma.
Association analysis of a polymorphism of the monoamine oxidase B gene with Parkinson's disease in a Japanese population.
Association between monoamine oxidase B A644G polymorphism and Parkinson's disease risk: a meta-analysis in the Chinese population.
Association of a monoamine oxidase B allele with Parkinson's disease.
Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease.
Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.
Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant.
Association of monoamine oxidase B alleles with age at onset in amyotrophic lateral sclerosis.
Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinson's disease in an Iranian population.
Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups.
Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface.
Binding mechanism of naringenin with monoamine oxidase - B enzyme: QM/MM and molecular dynamics perspective.
Biochemical actions of l-deprenyl (selegiline).
Boosting Drug Discovery for Parkinson's: Enhancement of the Delivery of a Monoamine Oxidase-B Inhibitor by Brain-Targeted PEGylated Polycaprolactone-Based Nanoparticles.
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease.
Can an adjuvant treatment or a pharmacologic prevention be common to several diseases? The case of those associated to neuromediator defects.
Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.
Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
Carnisone increases efficiency of DOPA therapy of Parkinson's disease: a pilot study.
Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease.
Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population.
Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.
Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment.
Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells.
Chronic alterations in jejunal myoelectric activity in rats due to MPTP.
Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites.
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway.
Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset.
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.
Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline.
Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
Clinical trials with rasagiline: evidence for short-term and long-term effects.
Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
Combining QSAR classification models for predictive modeling of human monoamine oxidase inhibitors.
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.
Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl.
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.
Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons.
Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
Deprenyl reduces the death of motoneurons caused by axotomy.
Deprenyl, a therapeutic agent for Parkinson's disease, inhibits arsenic toxicity potentiated by GSH depletion via inhibition of JNK activation.
Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors.
Design and synthesis of novel 3,4-dihydrocoumarins as potent and selective monoamine oxidase-B inhibitors with the neuroprotection against Parkinson's disease.
Design Expert(®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease.
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.
Design, Synthesis and Evaluation of 8-Thiosubstituted 1,3,7-Trimethylxanthine Hydrazones with In Vitro Neuroprotective and MAO-B Inhibitory Activities.
Design, Synthesis and Inhibitory Activities of 8-(Substituted styrol-formamido)phenyl-xanthine Derivatives on Monoamine Oxidase B.
Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Detection and analysis of four polymorphic markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with Parkinson's disease.
Detection of l-Methamphetamine and l-Amphetamine as Selegiline Metabolites.
Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Developing a Multi-target Model to Predict the Activity of Monoamine Oxidase A and B Drugs.
Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil.
Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson's disease.
Different generations of type-B monoamine oxidase inhibitors in Parkinson's disease: from bench to bedside.
Differential effects of selegiline on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies.
Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
Discovery, Biological Evaluation, and Structure-Activity and -Selectivity Relationships of 6'-Substituted (E)-2-(Benzofuran-3(2H)-ylidene)-N-methylacetamides, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors.
DNA sequence analysis of monoamine oxidase B gene coding and promoter regions in Parkinson's disease cases and unrelated controls.
Does phenylethylamine act as an endogenous amphetamine in some patients?
Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
Drug treatment of Parkinson's disease: current concepts.
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Dysregulation of astrocytic mitochondrial function following exposure to a dopamine metabolite: Implications for Parkinson's disease.
Early diagnosis of Parkinson's disease and initiation of treatment.
Early therapy for Parkinson's disease.
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
Effect of selegiline on cognitive functions in Parkinson's disease.
Effects of 1-cyclohexyl- and 1-cyclohexyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline on dopaminergic spontaneous discharge in nigral neurons of rats.
Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.
Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice.
Effects of Mitochondrial Antioxidant SkQ1 on Biochemical and Behavioral Parameters in a Parkinsonism Model in Mice.
Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells.
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study.
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Efficacy and tolerability of rasagiline in daily clinical use - a post-marketing observational study in patients with Parkinson's disease.
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.
Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders.
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele.
Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation.
Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage.
Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B.
Evaluation of the inhibitory effects of eckol and dieckol isolated from edible brown alga Eisenia bicyclis on human monoamine oxidases A and B.
Evaluation of the overall system precision of the Welch-Allyn transtelephonic home blood pressure monitor in adults with Parkinson's disease.
Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
Exploration of Umbelliferone Based Derivatives as Potent MAO Inhibitors: Dry vs. Wet Lab Evaluation.
Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson's Disease.
Exposing the Interplay Between Enzyme Turnover, Protein Dynamics, and the Membrane Environment in Monoamine Oxidase B.
Fluoxetine and selegiline--lack of significant interaction.
Free radicals in Alzheimer's dementia: currently available therapeutic strategies.
Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.
From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors.
Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands.
G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease.
Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug.
GAPDH as a sensor of NO stress.
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson's disease.
Gene-gene interaction between FGF20 and MAOB in Parkinson disease.
Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism.
Genetic polymorphism of monoamine oxidase B and susceptibility of Parkinson's disease.
Genetics and Parkinson's disease.
Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.
Herbal natural products as a source of monoamine oxidase inhibitors: a review.
Hereditary variation of liver enzymes involved with detoxification and neurodegenerative disease.
Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease.
High throughput Screening to Identify Natural Human Monoamine Oxidase B Inhibitors.
Highly efficient synthesis and monoamine oxidase B inhibitory profile of demethyleneberberine, columbamine and palmatine.
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening.
Hydroxytyrosol as anti-parkinsonian molecule: Assessment using in-silico and MPTP-induced Parkinson's disease model.
Hydroxytyrosol inhibits MAO isoforms and prevents neurotoxicity inducible by MPP+ invivo.
I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease.
Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson's Disease using In Silico Approach.
Impact of COMT H108L, MAOB int 13 A>G and DRD2 haplotype on the susceptibility to Parkinson's disease in South Indian subjects.
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
Improvement of mouse brain mitochondrial function after deprenyl treatment.
In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid.
In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain.
Increased L-dopa-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Influence of Single Nucleotide Polymorphisms in COMT , MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease.
Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration.
Inhibition of monoamine oxidase by benzoxathiolone analogues.
Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson's disease.
Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP+ Parkinson's disease models.
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
Inhibitory effect of drugs used in the treatment of Parkinson's disease on plasma monoamine oxidase activity.
Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors.
Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits.
Involvement of Bcl-2-associated athanogene (BAG)-family proteins in the neuroprotection by rasagiline.
Iron modulates the activity of monoamine oxidase B in SH-SY5Y cells.
Is selegiline neuroprotective in Parkinson's disease?
Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells.
Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid.
L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.
L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
L-deprenyl: nitric oxide production and dilation of cerebral blood vessels.
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Lack of protective effect of R(-)-deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone.
Laser modification of the blood in vitro and in vivo in patients with Parkinson's disease.
Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study.
Ligand based screening of chemical constituents from African medicinal plants for the identification of MAOB inhibitors.
Ligand-Based Virtual Screening Using Tailored Ensembles: A Prioritization Tool for Dual A2A Adenosine Receptor Antagonists / Monoamine Oxidase B Inhibitors.
Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
Lisuride plus selegiline in the treatment of early Parkinson's disease.
Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson's Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance.
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
Low Dosage of Rasagiline and Epigallocatechin Gallate Synergistically Restored the Nigrostriatal Axis in MPTP-Induced Parkinsonism.
M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
MAO-B and Parkinson's disease.
MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology.
MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([
MAO-B inhibitors for the treatment of Parkinson's disease.
MAO-B inhibitors in Parkinson's disease.
MAO-inhibitors in Parkinson's Disease.
MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Metabolic Control Analysis in a Cellular Model of Elevated MAO-B: Relevance to Parkinson's Disease.
Metabolic transformation of deprenyl enantiomers in rats.
Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
Methamphetamine and amphetamine derived from the metabolism of selegiline.
Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme.
Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy.
Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of rhesus monkey.
Milestones in Parkinson's disease therapeutics.
Mitochondrial-Targeted and Near-Infrared Fluorescence Probe for Bioimaging and Evaluating Monoamine Oxidase A Activity in Hepatic Fibrosis.
Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration.
Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.
Molecular characterization of monoamine oxidases A and B.
Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A(2A) Receptors for the Treatment of Parkinson's Disease.
Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Monoamine oxidase A and B inhibitors in Parkinson's disease.
Monoamine oxidase A inhibition and Parkinson's disease.
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Monoamine oxidase and ?-synuclein as targets in Parkinson's disease therapy.
Monoamine Oxidase and Dopamine ?-Hydroxylase Inhibitors from the Fruits of Gardenia jasminoides.
Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
Monoamine oxidase B and Parkinson's disease.
Monoamine oxidase B inhibitors for early Parkinson's disease.
Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
Monoamine oxidase B inhibitors in Parkinson's disease.
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: a study in an Asian population.
Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease.
Monoamine oxidase B, smoking, and Parkinson's disease.
Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat.
Monoamine oxidase inhibition by selected dye compounds.
Monoamine oxidase inhibitors and their pharmacological significance.
Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease.
Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson's Disease.
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Monoamine oxidase inhibitors. A perspective on their use in the elderly.
Monoamine oxidase inhibitors. An update on drug interactions.
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
Monoamine oxidase substrates in Parkinson's disease.
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease.
Monoamine oxidase, dopamine and Parkinson's disease.
Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
Monoamine oxidase-A promotes protective autophagy in human SH-SY5Y neuroblastoma cells through Bcl-2 phosphorylation.
Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.
Monoamine Oxidase-B Inhibition Facilitates ?-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.
Monoamine oxidase-B inhibition in Alzheimer's disease.
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Monoamine Oxidases.
Monoamineoxidase-B (MAO-B) Inhibitors in theTreatment of Alzheimer's and Parkinson's Disease.
Morphological and biochemical changes in the aging brain: pathophysiological and possible therapeutic consequences.
Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
Multicenter trial of L-Deprenyl in Parkinson disease.
Multiscale Modeling of Two-Photon Probes for Parkinson's Diagnostics Based on Monoamine Oxidase B Biomarker.
My love with monoamine oxidase, iron and Parkinson's disease.
Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors.
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline).
Neurochemical perspectives to the function of monoamine oxidase.
Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration.
Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition.
Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease.
Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1? signaling pathway and mitochondrial uncoupling protein -2(UCP-2).
Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion.
Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
Neuroprotective effects of the MAO-B inhibitor, PF9601N, in an in vivo model of excitotoxicity.
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Neurorescuing effects of the GAPDH ligand CGP 3466B.
Neurotoxins and monoamine oxidase inhibition: new aspects.
New directions in monoamine oxidase A and B selective inhibitors and substrates.
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
New role for crinamine as a potent, safe and selective inhibitor of human monoamine oxidase B: In vitro and in silico pharmacology and modeling.
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.
No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms.
Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.
Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson's disease therapy.
Novel Diels-Alder Type Adducts from Morus alba Root Bark Targeting Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases.
Novel Food Supplement "CP1" Improves Motor Deficit, Cognitive Function, and Neurodegeneration in Animal Model of Parkinson's Disease.
Novel MAO-B inhibitors potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility.
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
On the functions of monoamine oxidase, the emotions, and adaptation to stress.
Orally disintegrating selegiline for the treatment of Parkinson's disease.
Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson's disease.
Oxidative stress and antioxidant therapy in Parkinson's disease.
Oxidative Stress Indices in Parkinson's Disease : Biochemical Determination.
Oxy-radical toxicity in catecholamine neurons.
Pain in Parkinson's disease: new concepts in pathogenesis and treatment.
Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.
Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.
Parkinson's Disease Management. Part II- Discovery of MAO-B Inhibitors Based on Nitrogen Heterocycles and Analogues.
Parkinson's disease.
Parkinson's disease: clinical and therapeutic aspects.
Parkinson's disease: diagnosis and treatment.
Parkinson's disease: fewer treatment withdrawals with levodopa.
Parkinson's disease: focus on management alternatives.
Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein-Inhibitor Complexes in Relevance to Developing Parkinson's Therapeutics.
Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease.
Perspectives on MAO-B in aging and neurological disease: where do we go from here?
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
Pharmacodynamics of MDL 72974A: absence of effect on the pressor response to oral tyramine.
Pharmacokinetic characteristics of agents applied in the treatment of Parkinson's disease.
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status.
Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.
Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors.
Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.
Pharmacological and clinical implications of MAO-B inhibitors.
Pharmacological aspects of (-)-deprenyl.
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.
Pharmacology of selegiline.
Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO?B inhibitors.
Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B.
Phytochemical investigation of some traditional chinese medicines and endophyte cultures.
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Platelet MAO activities and MAO-B protein concentrations in Parkinson's disease and controls.
Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation.
Platelet monoamine oxidase B activity in parkinsonian patients.
Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
Platelet monoamine oxidase-B activity in Parkinson's disease.
Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson's disease.
Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.
Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.
Potent Selective Inhibition of Monoamine Oxidase A by Alternariol Monomethyl Ether Isolated from Alternaria brassicae.
Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens.
Practical considerations for the treatment of elderly patients with migraine.
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Preclinical Herb-Drug Pharmacokinetic Interaction of Panax ginseng Extract and Selegiline in Freely Moving Rats.
Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease.
Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
Progress in monoamine oxidase (MAO) research in relation to genetic engineering.
Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.
Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.
Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
Protein aggregation in retinal cells and approaches to cell protection.
Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson's disease.
R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
R-(-)-deprenyl in the treatment of end-of-dose akinesia.
R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
Rapid onset of efficacy of rasagiline in early Parkinson's disease.
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.
Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.
Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rasagiline derivatives combined with histamine H3 receptor properties.
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia.
Rasagiline for sleep disorders in patients with Parkinson's disease: a prospective observational study.
Rasagiline in Parkinson's disease.
Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
Rasagiline in the pharmacotherapy of Parkinson's disease - a review.
Rasagiline in treatment of Parkinson's disease.
Rasagiline induced hypersexuality in Parkinson's disease.
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Rasagiline, a Suicide Inhibitor of Monoamine Oxidases, Binds Reversibly to ?-Synuclein.
Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content.
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
Rationally designed multi-targeted agents against neurodegenerative diseases.
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Recent advances in pharmacological therapy of Parkinson's disease.
Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis.
Reduced striatal tyrosine hydroxylase activity is not accompanied by change in responsiveness of dopaminergic receptors following chronic treatment with deprenyl.
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Ring opening of pymisyl-protected aziridines with organocuprates.
Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
Safinamide (Newron Pharmaceuticals).
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Safinamide in the treatment of Parkinson's disease.
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Safinamide prevents lipopolysaccharide (LPS)-induced inflammation in macrophages by suppressing TLR4/NF-?B signaling.
Selected chromone derivatives as inhibitors of monoamine oxidase.
Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana).
Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.
Selective inhibitors of monoamine oxidase type B and the "cheese effect".
Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease.
Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
Selegiline and cognitive function in Parkinson's disease.
Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Selegiline as immunostimulant--a novel mechanism of action?
Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.
Selegiline for Parkinson's disease.
Selegiline in Parkinson's disease.
Selegiline in the treatment of narcolepsy.
Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms.
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Selegiline transdermal system: in the treatment of major depressive disorder.
Selegiline treatment facilitates recovery after stroke.
Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
Selegiline: a molecule with innovative potential.
Selegiline: a reappraisal of its role in Parkinson disease.
Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.
Seligiline transdermal system in depression.
Sex-dependent monoamine oxidase isoforms expression patterns during human brain ageing.
Short review on monoamine oxidase and its inhibitors.
Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?
Simultaneous bioanalysis of rasagiline and its major metabolites in human plasma by LC-MS/MS: Application to a clinical pharmacokinetic study.
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Single heterocyclic compounds as Monoamine Oxidase Inhibitors: From past to present.
Sizes and ligands tuned gold nanocluster acting as a new type of monoamine oxidase B inhibitor.
Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.
SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.
Steered molecular dynamics simulations reveal important mechanisms in reversible monoamine oxidase B inhibition.
Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors.
Structure-based design and analysis of MAO-B inhibitors for Parkinson's disease: using in silico approaches.
Successful use of rasagiline in combination with two antidepressants: a case report.
Suicide inhibition of monoamine oxidases A and B by (-)-deprenyl. A computer-aided solution for determining inhibition specificity.
Symmetrical aryl linked bis-iminothiazolidinones as new chemical entities for the inhibition of monoamine oxidases: Synthesis, in vitro biological evaluation and molecular modelling analysis.
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).
Synthesis and Evaluation of 2-benzylidene-1-tetralone Derivatives for Monoamine Oxidase Inhibitory Activity.
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase.
Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors.
Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents.
Synthetic approaches to unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles and their MAO-B inhibitory activity. A review.
The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells.
The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.
The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
The EcoRV genetic polymorphism of human monoamine oxidase type A is not associated with Parkinson's disease and does not modify the effect of smoking on Parkinson's disease.
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
The effect of deprenyl washout in patients with long-standing Parkinson's disease.
The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials.
The effects of pyridinium salts, structurally related compounds of 1-methyl-4-phenylpyridinium ion (MPP+), on tyrosine hydroxylation in rat striatal tissue slices.
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study.
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase.
The hypothalamus in MPTP-induced parkinsonism.
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.
The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
The molecular pharmacology of L-deprenyl.
The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population.
The monoamine oxidase inhibition properties of C6-mono- and N3/C6-disubstituted derivatives of 4(3H)-quinazolinone.
The monoamine oxidase inhibitory activity of essential oils obtained from Eryngium species and their chemical composition.
The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?
The new generation of monoamine oxidase inhibitors.
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
The Pathological Role of Astrocytic MAOB in Parkinsonism Revealed by Genetic Ablation and Over-expression of MAOB.
The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue.
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
The pharmacology of selegiline.
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
The relationship between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease risk: a meta-analysis.
The relationship of early studies of monoamine oxidase to present concepts.
The relationship of negative schizophrenia to parkinsonism.
The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment.
The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease.
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
The Synthesis and Evaluation of C7-Substituted ?-Tetralone Derivatives as Inhibitors of Monoamine Oxidase.
The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase.
The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
The Use of Multiscale Molecular Simulations in Understanding a Relationship between the Structure and Function of Biological Systems of the Brain: The Application to Monoamine Oxidase Enzymes.
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Theoretical Study of Monoamine Oxidase B Inhibitors as Drug Candidates for Treatment of Parkinson's Disease.
Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib.
Tight-Binding Inhibition of Human Monoamine Oxidase B by Chromone Analogs: A Kinetic, Crystallographic, and Biological Analysis.
Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?
Total monoamine oxidase (MAO) inhibition by chestnut honey, pollen and propolis.
Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response.
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future challenges - A Mini-Review.
Treatment of Parkinson's disease.
Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells.
Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Type B monoamine oxidase and neurotoxins.
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release.
Using monoamine oxidase type B inhibitors in Parkinson's disease.
Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease.
Virtual screening and drug repurposing experiments to identify potential novel selective MAO-B inhibitors for Parkinson's disease treatment.
What a Difference a Methyl Group Makes: The Selectivity of Monoamine Oxidase?B Towards Histamine and N-Methylhistamine.
Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients.
X-LRT: a likelihood approach to estimate genetic risks and test association with X-linked markers using a case-parents design.
Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson's Disease.
Zhichan powder regulates nigrostriatal dopamine synthesis and metabolism in Parkinson's disease rats.
Zonisamide: a new drug for Parkinson's disease.
Zydis selegiline in the management of Parkinson's disease.
[Application of the common marmoset to pharmacological studies]
[Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution]
[Comorbid states in Parkinson's disease: an effect of MAO-B inhibitors].
[Current therapy of idiopathic Parkinson disease. 2: Recent and alternative therapies]
[Do monoamine oxidase B inhibitors represent hope for Parkinson's disease patients?]
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
[Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].
[Impact of rhythmic transcranial magnetic stimulation on the dynamics of motor and non-motor manifestations of Parkinson's disease].
[Inhibitory monoamine oxidases of the new generation]
[Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease]
[Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]
[Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals (author's transl)]
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]
[Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect®)].
[Pharmacological treatments of Parkinson's disease]
[Plasma levels of mediator amino acids in patients with Parkinson disease]
[Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene in Parkinson's disease]
[Polymorphisms of catechol-O-methyltransferase and monoamine oxidase B genes among Chinese patients with Parkinson's disease].
[Positron emission tomography of C-11-labelled selegiline]
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].
[Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals]
[Relationship between the Fnu4HI site polymorphism of monoamine oxidase A gene and Parkinson's disease]
[Role of gene polymorphism of catechol-O-methyltransferase (COMT), monoamine oxidase B (MAOB), cytochrome P450 2D6 (CYP2D6) and N-acetyltransferase 2 (NAT2) in pathogenesis of Parkinson's disease]
[Safinamide Mesilate (Equfina® TABLETS 50?mg): preclinical and clinical pharmacodynamics, efficacy, and safety].
[Severe therapy refractory depression as initial manifestation of Parkinson disease]
[The EcoR V polymorphism of human monoamine oxidase A is not associated with idiopathic Parkinson's disease in a Shanghai Han population]
[The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
[The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
[The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].
[The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease]
[Tobacco--once a medicinal plant. Does it contain substances with medicinal properties?].
Parkinsonian Disorders
1-Methyl-4-phenylpyridinium (MPP+) binds with high affinity to a beta-carboline binding site located on monoamine oxidase type A in rat brain.
1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: inhibitory effects of several drugs.
A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice.
Ameliorative effect of ethoxylated chalcone-based MAO-B inhibitor on behavioural predictors of haloperidol-induced Parkinsonism in mice: evidence of its antioxidative role against Parkinson's diseases.
Antiparkinsonian Effects of Aqueous Methanolic Extract of Hyoscyamus niger Seeds Result From its Monoamine Oxidase Inhibitory and Hydroxyl Radical Scavenging Potency.
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Biochemical actions of l-deprenyl (selegiline).
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Cerebral metabolic effects of monoamine oxidase inhibition in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine acutely treated monkeys.
Cytotoxicity of 1-amino-4-phenyl-1,2,3,6-tetrahydropyridine and 1-amino-4-phenylpyridinium ion, 1-amino analogues of MPTP and MPP+, to clonal pheochromocytoma PC12 cells.
Deprenyl in Parkinson disease.
Deprenyl monotherapy improves visuo-motor control in early parkinsonism.
Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group.
Dopamine efflux by MPTP and hydroxyl radical generation.
Drug treatment of Parkinson's disease: current concepts.
Early idiopathic parkinsonism: initiation and optimization of treatment.
Environmental estrogen-like chemicals and hydroxyl radicals induced by MPTP in the striatum: a review.
Fracture risk associated with parkinsonism and anti-Parkinson drugs.
Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson's disease.
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors.
Inhibition of type A monoamine oxidase by 1-methyl-4-phenylpyridine.
Isoquinoline neurotoxins in the brain and Parkinson's disease.
Medical Management of Frontotemporal Dementias: The Importance of the Caregiver in Symptom Assessment and Guidance of Treatment Strategies.
Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.
Molecular characterization of monoamine oxidases A and B.
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Neurotoxicity of MPTP.
Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).
Parkinson's disease: past, present, and future.
Parkinsonian side effects induced by a monoamine oxidase inhibitor.
Parkinsonism induced by a monoamine oxidase inhibitor.
Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions.
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain.
Platelet monoamine oxidase B activity in parkinsonian patients.
Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.
Prevalence of parkinsonism estimated using the drug prescription archive: a possible method to estimate the prevalence of a chronic neurological disease?
Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping.
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Short review on monoamine oxidase and its inhibitors.
Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide.
The effect of deprenyl treatment on directional and velocity control of arm movement in patients with early stages of Parkinson's disease.
The effect of L-Deprenyl on on-off phenomena in Parkinson's disease.
The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.
The hypothalamus in MPTP-induced parkinsonism.
The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population.
The monoamine-oxidase B inhibitor deprenyl increases selection of high-effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treating motivational dysfunctions.
The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease.
[Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients]
[Parkinsonism induced by MPTP and free radical generation]
Peptic Ulcer
Treatment of peptic ulcer disease with furazolidone.
[Intravital histopathological changes in the gastric mucosa and the activity of certain cytoplasmic enzymes (cholinesterase, monoamine oxidase, histaminase) and acetylcholine in peptic ulcer and chronic gastritis]
Peripheral Arterial Disease
Preliminary observations on the role of monoamine oxidase inhibitors in the therapy of peripheral arterial disease.
Peripheral Vascular Diseases
THE PLACE OF MONOAMINE OXIDASE INHIBITOR IN OCCLUSIVE PERIPHERAL VASCULAR DISEASE.
Pharyngeal Neoplasms
Genetic and Proteinic Linkage of MAO and COMT with Oral Potentially Malignant Disorders and Cancers of the Oral Cavity and Pharynx.
The influence of monoamine oxidase variants on the risk of betel quid-associated oral and pharyngeal cancer.
Phenylketonurias
Is monoamine oxydase-B a modifying gene and phenylethylamine a harmful compound in phenylketonuria?
Monoamine oxidase inhibitors in tetrahydrobiopterin deficiency.
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Pheochromocytoma
1,4-Benzoquinone as a new inhibitor of monoamine oxidase.
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase.
An adrenal mass and increased catecholamines: monoamine oxidase or pheochromocytoma effect?
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Cytotoxic, cytoprotective and antioxidant effects of isolated phenolic compounds from fresh ginger.
Dopamine and iron induce apoptosis in PC12 cells.
Effect of antioxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells.
Effect of N-methyl-4-phenylpyridinium ion on monoamine oxidase in a clonal rat pheochromocytoma cell line, PC12h.
Ganglioside GM1 causes expression of type B monoamine oxidase in a rat clonal pheochromocytoma cell line, PC12h.
Hypertensive emergencies. Etiology and management.
Inhibition of monoamine oxidase by metaiodobenzylguanidine, a new radiodiagnostic agent.
Inhibition of type A monoamine oxidase by methylquinolines and structurally related compounds.
Metabolism and storage of catecholamines in rats with pheochromocytoma implants.
Monoamine oxidase a down-regulation contributes to high metanephrine concentration in pheochromocytoma.
Monoamine oxidase in rat and bovine endocrine tissues.
Monoamine oxidase types A and B in the human adrenal gland and pheochromocytoma.
N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Oxidation of 1-amino-4-phenyl-1,2,3,6-tetrahydropyridine, a 1-amino analog of MPTP, by type A and B monoamine oxidase.
Serotonin metabolism and platelet monoamine oxidase activity in patients with medullary carcinoma of the thyroid and pheochromocytoma.
The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?
Photophobia
MAOA and TNF-? gene polymorphisms are associated with photophobia but not osmophobia in patients with migraine.
Photosensitivity Disorders
Photosensitizing effects of Photofrin II on the site-selected mitochondrial enzymes adenylate kinase and monoamine oxidase.
Pick Disease of the Brain
Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease.
Pituitary Neoplasms
Densities of I2-imidazoline receptors, imidazoline receptor proteins, and MAO-B sites in human gliomas and pituitary adenomas.
Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats.
Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl.
Positron emission tomography in acromegaly and other pituitary adenoma patients.
Pneumococcal Infections
[Change in activity of 5-oxytryptophan decarboxylase and monoamine oxidase in rat organs in experimental pneumococcal infection]
[EFFECT OF INDOPAN, A MONOAMINE OXIDASE INHIBITOR, ON THE TETRACYCLINE SENSITIVITY OF WHITE MICE AND RATS WITH PNEUMOCOCCAL INFECTION.]
Pneumoconiosis
[Monoamine oxidase activity in pneumoconiosis]
Pneumonia
Synthesis and antibacterial activities of new piperidine substituted (5R)-[1,2,3]triazolylmethyl and (5R)-[(4-F-[1,2,3]triazolyl)methyl] oxazolidinones.
Polycystic Ovary Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Prader-Willi Syndrome
Is monoamine oxidase activity elevated in Prader-Willi syndrome?
Pre-Eclampsia
A high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type 1 diabetes.
Dopamine in the Pathophysiology of Preeclampsia and Gestational Hypertension: Monoamine Oxidase (MAO) and Catechol-O-methyl Transferase (COMT) as Possible Mechanisms.
Monoamine oxidase expression and activity in human placentae from pre-eclamptic and normotensive pregnancies.
Semicarbazide-sensitive amine oxidase in pre-eclampsia: no relation with markers of endothelial cell activation.
Serotonin metabolism in the fetus in preeclampsia.
The expression and activity of monoamine oxidase A, but not of the serotonin transporter, is decreased in human placenta from pre-eclamptic pregnancies.
Transport and metabolism of serotonin in the human placenta from normal and severely pre-eclamptic pregnancies.
[Blood plasma dopamine beta-hydroxylase and monoamine oxidase activity in pregnancy toxemias]
[Concentration of serotonin (5-HT) and monoamine oxidase activity in the placentas of women with pregnancy toxemias]
[Determination in Warburg apparatus of the monoamine oxidase activity of the placenta in normal pregnancy and in preeclampsia]
[Levels of serotonin in plasma and activity of monoamine oxidase in serum and blood platelets of women with EPH gestosis]
[Study on serotonin metabolism in toxemia of pregnancy]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Effect of phenelzine on the proliferation, apoptosis and histone methylation and acetylation of Molt-4 cells].
Pregnancy, Ectopic
Ketamine induction and monoamine oxidase inhibitors.
Pregnancy, High-Risk
Monoamine oxidase activity in the term human placenta.
Premenstrual Dysphoric Disorder
Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder.
Transcription factor AP-2 and monoaminergic functions in the central nervous system.
Prolactinoma
Erythrocyte catechol-O-methyltransferase, platelet monoamine oxidase, and platelet phenol sulfotransferase activities in patients with prolactin-secreting pituitary adenomas.
Prostatic Hyperplasia
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Prostatic Neoplasms
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells.
Antidepressants protect bones from metastatic prostate cancer.
Application of novel pH sensitive isoniazid-heptamethine carbocyanine dye conjugates against prostate cancer cells.
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer.
Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1? signaling.
Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.
Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells.
Elevated activity of semicarbazide-sensitive amine oxidase in blood from patients with skeletal metastases of prostate cancer.
Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats.
Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo.
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells.
Kava root extracts hinder prostate cancer development and tumorigenesis by involvement of dual inhibition of MAO-A and LSD1.
MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Monoamine oxidase-A targeting probe for prostate cancer imaging and inhibition of metastasis.
Novel 4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains: design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis and tumor cell.
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Repurposing antitubercular agent isoniazid for treatment of prostate cancer.
Serotonin synthesis and metabolism-related molecules in a human prostate cancer cell line.
Targeting monoamine oxidase A in advanced prostate cancer.
The effects of tranylcypromine on osteoclastogenesis in vitro and in vivo.
The Monoamine Oxidase A gene promoter repeat and prostate cancer risk.
The significance of monoamine oxidase-A expression in high grade prostate cancer.
Protein Deficiency
Protein malnourishment: a predisposing factor in acrylamide toxicity in pregnant rats.
Psoriasis
Monoamine- and diamine oxidase activities in psoriasis.
Psychomotor Agitation
Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs.
Pulmonary Arterial Hypertension
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Pulmonary Disease, Chronic Obstructive
Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells.
The involvement of serotonin metabolism in cigarette smoke-induced oxidative stress in rat lung in vivo.
[Comparative clinical studies of the hemodynamic parameters by anesthesia combination with Nalbuphin (Nubain) and Fentanyl]
Pulmonary Edema
A role for serotonin in alpha-naphthylthiourea-induced pulmonary edema.
[Influence of monoamine oxidase inhibitors on acute pulmonary edema induced by inhalation of ozone]
Purpura
Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density.
Purpura, Thrombocytopenic
Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density.
Purpura, Thrombocytopenic, Idiopathic
Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density.
Reflex, Abnormal
Phenelzine toxicity responsive to dantrolene.
Renal Insufficiency
Abstracts of the 5th joint meeting of the german, austrian, and swiss sections of the international league against epilepsy basle, may 16-19, 2007.
[Comparative clinical studies of the hemodynamic parameters by anesthesia combination with Nalbuphin (Nubain) and Fentanyl]
Renal Insufficiency, Chronic
Increased serum renalase in peritoneal dialysis patients: Is it related to cardiovascular disease risk?
Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition.
Semicarbazide-sensitive amine oxidase and kidney disease.
Reperfusion Injury
Cardiomyocytes-specific deletion of monoamine oxidase B reduces irreversible myocardial ischemia/reperfusion injury.
Elevated semicarbazide-sensitive amine oxidase (SSAO) activity in lung with ischemia-reperfusion injury: protective effect of ischemic preconditioning plus SSAO inhibition.
Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress.
Inhibition of semicarbazide-sensitive amine oxidase attenuates myocardial ischemia-reperfusion injury in an in vivo rat model.
Monoamine oxidase inhibition prevents ischemia reperfusion damage in rat kidneys.
Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury.
Synthesis and identification of a novel derivative of salidroside as a selective, competitive inhibitor of monoamine oxidase B with enhanced neuroprotective properties.
Restless Legs Syndrome
Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia.
Evidence for a genetic association between monoamine oxidase A and restless legs syndrome.
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Retinal Detachment
[Monoamine oxidase activity in retinal detachment]
Retinitis Pigmentosa
Studies on retinitis pigmentosa. I. Monoamine oxidase and sulfate conjugation in the experimental degeneration of the retina.
Reye Syndrome
Absence of diffusible inhibitor of glutamate dehydrogenase in the hepatocytes of Reye syndrome patients.
Hepatic monoamine oxidase deficiency in Reye syndrome.
Platelet-monoamine oxidase activity in Reye's syndrome.
Quantitative evaluation of the extent of hepatic enzyme changes in Reye syndrome compared with normal liver or with non-Reye liver disorders: objective criteria for animal models.
Salicylate and mitochondrial monoamine oxidase function in Reye's syndrome.
Rhabdomyolysis
[Hyperthermia and rhabdomyolysis caused by a monoamine oxidase inhibitor]
Rheumatic Diseases
The use of psychotropic drugs in rheumatology.
[Activity of serum monoamine oxidase in rheumatism]
[Concentration of catecholamines, their precursors, vanilmandelic acid and monoamine oxidase in patients with rheumatism in the active phase]
Rheumatic Fever
[Activity of serum monoamine oxidase in rheumatic fever and rheumatoid arthritis]
Rheumatic Heart Disease
[Monoamine oxidase activity in rheumatic heart disease associated with symptomatic hypertension]
Sarcoma
[The vehaviour of monoaminooxydase (MAO) activity in tumours. I. MAO activity measurement in experimental tumours (author's transl)]
Sarcoma 37
[Monoamine oxidase activity in cell nuclei and nuclear fractions of mouse liver under normal conditions and during development of ascitic sarcoma 37]
Sarcoma, Avian
[Activity of monoamine oxidase and diamine oxidase in a culture of chick fibroblasts infected with Rous sarcoma virus]
Sarcoma, Kaposi
HISTOCHEMISTRY OF KAPOSI'S SARCOMA. II. CHOLINESTERASES, MONOAMINE OXIDASE, AND ADENOSINE TRIPHOSPHATASE.
Schistosomiasis mansoni
Serum enzyme tests in hepatosplenic schistosomiasis.
Scrapie
Alteration of free radical metabolism in the brain of mice infected with scrapie agent.
Seizures
(+/-)-4-Aryl-4,5-dihydro-3H-1,3-benzodiazepines. 1. Synthesis and evaluation of (+/-)-4,5-dihydro-2,3-dimethyl-4-phenyl-3H-1,3-benzodiazepine and analogues as potential antidepressant agents.
Abstracts of the 5th joint meeting of the german, austrian, and swiss sections of the international league against epilepsy basle, may 16-19, 2007.
Anti-convulsant activity of diazepam and clonidine on metaldehyde-induced seizures in mice: effects on brain gamma-amino butyric acid concentrations and monoamine oxidase activity.
Anticonvulsant effects of intracerebroventricularly administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure genetically epilepsy-prone rats (GEPR-9s).
Anticonvulsant efficacy of L-deprenyl (selegiline) during chronic treatment in mice: continuous versus discontinuous administration.
Bupropion sustained release. A therapeutic review of Zyban.
Can disulfiram (Antabuse) be safely co-administered with the monoamine oxidase inhibitor (MAOI) antidepressants? Despite the ability of the major metabolite of disulfiram (diethyldithiocarbamate) to inhibit the enzyme dopamine beta-hydroxylase and a report of the induction in rats of central motor disturbances, convulsions, and death following the co-administration of tranylcypromine, there appears to be surprisingly little in the literature that directly addresses this question.
Catechol-O-methyl transferase and monoamine oxidase activities in brains of mice susceptible and resistant to audiogenic seizures.
Chronic administration of citalopram inhibited El mouse convulsions and decreased monoamine oxidase-A activity.
Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.
Combined inhibition of serotonin uptake and oxidative deamination attenuates audiogenic seizures in DBA/2J mice.
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Do SSRIs prolong seizure duration during ECT?
Effect of postnatal anoxia on seizure susceptibility in rats: bicuculline-induced seizures and pretreatment with iproniazid.
Effect of pretreatment with monoamine oxidase inhibitors or (+)-amphetamine on leptazol convulsions in mice and rats.
Electroconvulsive shock increases endogenous monoamine oxidase inhibitor activity in brain and cerebrospinal fluid.
Expression pattern of NMDA receptors reveals antiepileptic potential of apigenin 8-C-glucoside and chlorogenic acid in pilocarpine induced epileptic mice.
Flumazenil and seizures: analysis of 43 cases.
General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on central nervous and sensory systems and other functions.
Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.
In vivo monoamine oxidase inhibition measured by potentiation of tryptamine convulsions in rats.
Increase of brain endogenous monoamine oxidase inhibitory activity (tribulin) in experimental audiogenic seizures in rats: evidence for a monoamine oxidase A inhibiting component of tribulin.
Increased monoamine oxidase activity following repeated electroshock seizures.
Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase.
MAO(A) knockout mice are more susceptible to seizures but show reduced epileptogenesis.
MAO-B inhibitor deprenyl and beta-phenylethylamine potentiate [D-ALA2]-Met-enkephalinamide-induced seizures.
Medically serious adverse effects of newer antidepressants.
New CNS-active 3-methyl-4-substituted methyl-delta 2-isoxazolin-5-ones.
Platelet and brain GABA-transaminase and monoamine oxidase activities in patients with complex partial seizures.
Search for newer substituted phenoxyacetylethyleneimines as possible CNS, MAO and anticonvulsant agents.
Seizures associated with antidepressants: a review.
Seizures in a diabetic patient on monoamine oxidase inhibitors.
Seizures with neuroleptics and antidepressants.
Synthesis of substituted anilino-3-methoxy-4-substituted acetoxy) benzylidenes and their monoamine oxidase inhibitory and anticonvulsant properties.
Temporal profile of aminergic neurotransmitter release in striatal dialysates in rats with post-ischemic seizures.
The dose-response ratio in electroconvulsive therapy a preliminary study.
The effect of monoamine oxidase inhibitor and amine precursors on epileptic seizures.
The epidemiology of depression and the evolution of treatment.
[Biochemical indices of the sensitivity of cold-adapted animals to hyperoxic exposure]
[Effect of a monoamine oxidase inhibitor on the level of seizure readiness and functional asymmetry of the brain]
[Effect of benzamide derivatives on convulsions induced by the toxic action of oxygen in rats]
[Effect of cold adaptation and brief exposure to cold on the resistance of animals to hypoxic hypoxia]
[Histochemical and image-analytic study of the rat locus coeruleus during status epilepticus]
[Monoamine oxidase activity and effect of clorgyline on the polyamine level during hyperoxia in rats]
[Monoamine oxidase and diamine oxidase activity of the tissues of rats in the convulsive phase of oxygen poisoning]
sepiapterin reductase (l-erythro-7,8-dihydrobiopterin forming) deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Shy-Drager Syndrome
Monoamine oxidase inhibitors and Sinemet in Shy-Drager syndrome.
[Case of Shy-Drager syndrome with an effective response to a monoamine oxidase inhibitor and cheese therapy--evaluation of catecholamine metabolism]
Skin Diseases
[Blood monoamine oxidase activity and erythrocyte membrane permeability in patients with allergic dermatoses]
Sleep Apnea Syndromes
Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.
Sleep apneas are increased in mice lacking monoamine oxidase A.
Sleep Apnea, Central
Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.
Sleep Apnea, Obstructive
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Sleep Deprivation
Activities of monoamine oxidase (MAO) A and B in discrete regions of rat brain after rapid eye movement (REM) sleep deprivation.
Alterations of blood platelet MAO-B activity and LSD-binding in humans after sleep deprivation and recovery sleep.
Decreased activity of striatal monoamine oxidase B after rapid eye movement (REM) sleep deprivation in rats.
Effect of rapid eye movement sleep deprivation on rat brain monoamine oxidases.
Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study.
Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5HT1C receptor activation in rats.
Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.
Monoamine oxidase activity in platelets before and after sleep deprivation as predictor for antidepressive drug response.
Possible mechanism of rapid eye movement sleep deprivation induced increase in Na-K ATPase activity.
Sleep disturbance as detected by actigraphy in pre-pubertal juvenile monkeys receiving therapeutic doses of fluoxetine.
[Rapid eye-movement sleep for five days deprivation causes delayed depressive-like behavior in mice].
Sleep Initiation and Maintenance Disorders
(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Antidepressants and their effect on sleep.
Insomnia, platelet serotonin and platelet monoamine oxidase in chronic alcoholism.
Liquid chromatography-mass spectrometry in-depth analysis and in silico verification of the potential active ingredients of Baihe Dihuang decoction in vivo and in vitro.
Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study.
Management of monoamine oxidase inhibitor-associated insomnia with trazodone.
The effects of trazodone on sleep disturbances induced by brofaromine.
Withdrawal phenomena associated with antidepressant and antipsychotic agents.
Sleep Wake Disorders
Rasagiline for sleep disorders in patients with Parkinson's disease: a prospective observational study.
Spinal Cord Injuries
Effect of acetylcholine in rat brain in promoting early recovery of spinal cord injury by inhibiting monoamine oxidase enzyme: A pre-clinical evidence.
Staphylococcal Infections
[Separate and combined action of antibiotics and vitamins on monoamine oxidase activity of the rabbit liver in staphylococcal infection]
Starvation
Effect of acute starvation on monoamine oxidase and Na+,K(+)-ATPase activity in rat brain.
Effect of starvation and pattern of feeding upon activities of enzymes catechol-O-methyltransferase and monoamine oxidase in heart and liver of developing rats.
Influence of progressive starvation upon brain and adrenal monoaminergic activity in developing rats of two different ages.
Serotonergic and tryptaminergic overstimulation on refeeding implicated in "enlightenment" experiences.
Variations in mitochondrial monoamine oxidase during progressive starvation in the brain of developing rats.
Stillbirth
Association of dopamine transporter and monoamine oxidase molecular polymorphisms with sudden infant death syndrome and stillbirth: new insights into the serotonin hypothesis.
Stomach Neoplasms
Antidepressants and Gastric Cancer: A Nationwide Population-Based Nested Case-Control Study.
Enzyme activities in human gastric cancer and polyps.
Monoamine Oxidase A is a Major Mediator of Mitochondrial Homeostasis and Glycolysis in Gastric Cancer Progression.
Promotion by nialamide of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
Stomach Ulcer
L-deprenyl attenuates stress ulcer formation in rats.
[Mitochondrial monoamine oxidase in the brain, stomach and liver in experimental gastric ulcer and the change in their activity under the influence of quateron]
Stroke
Alcohol free beer link with strokes.
Drug-induced hyperpyrexia. A case report.
Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option.
Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes Functional Recovery after Subcortical Stroke.
Long-term food restriction, deprenyl, and nimodipine treatment on life expectancy and blood pressure of stroke-prone rats.
Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.
Plasma semicarbazide-sensitive amine oxidase in stroke.
Post-Stroke Fatigue May Be Associated with the Promoter Region of a Monoamine Oxidase A Gene Polymorphism.
Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats.
Safinamide (Newron Pharmaceuticals).
Stupor
Stupor from dextroamphetamineamobarbital and monoamine oxidase inhibitor, phenelzine.
Stuttering
Neurogenic stuttering and lateralized motor deficits induced by tranylcypromine.
Subarachnoid Hemorrhage
Monoamine oxidase inhibitors and subarachnoid hemorrhage.
succinate-semialdehyde dehydrogenase [nad(p)+] deficiency
Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the iNTD registry.
Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.
Supranuclear Palsy, Progressive
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy.
Tachycardia
"Ping-pong" gaze in severe monoamine oxidase inhibitor toxicity.
Acute myocarditis after massive phenelzine overdose.
Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study.
Phenelzine toxicity responsive to dantrolene.
Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs.
Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults.
St. John's wort: a new alternative for depression?
Tardive Dyskinesia
A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
An inverse correlation between spontaneous eye-blink rate and platelet monoamine oxidase activity.
Enzyme studies in tardive dyskinesia. I. One-year biochemical follow-up.
Enzyme studies in tardive dyskinesia. II. Familial aspects.
Ex uno multi: subtyping the schizophrenic syndrome.
Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia.
Monoamine oxidase inhibitors antagonize the acceleration of brain dopamine synthesis induced by neuroleptic drugs in vivo: implications for the treatment of Tardive dyskinesia.
Platelet monoamine oxidase activity and tardive dyskinesia.
Platelet monoamine oxidase and plasma dopamine beta-hydroxylase in tardive dyskinesia.
Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
Tauopathies
Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H2O2- production.
Tension-Type Headache
Association analysis of the functional MAOA gene promoter and MAOB gene intron 13 polymorphisms in tension type headache patients.
Platelet monoamine oxidase activity and headache.
Teratoma
Neurochemical studies in a mouse teratoma with neuroepithelial differentiation. Presence of cyclic AMP, serotonin and enzymes of the serotonergic, adrenergic and cholinergic systems.
Thiamine Deficiency
Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency.
Thrombocytopenia
Linezolid: new preparation. In severe gram-positive infections.
[Inactivation of serotonin in patients with hemorrhagic fever with kidney syndrome]
Thrombocytosis
Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density.
Thrombosis
Effects of monoamine oxidase inhibitors, glyceryl gualacolate, and ethanol on experimental arterial thrombosis.
[THE ACTION OF A MONOAMINE OXIDASE INHIBITOR ON THE SIZE OF VENOUS AND ARTERIAL THROMBOSES.]
Thyroid Diseases
Monoamine oxidase activity of the thyroid glands in thyroid disease.
Ultrastructural localization of thyroid peroxidase, hydrogen peroxide-generating sites, and monoamine oxidase in benign and malignant thyroid diseases.
[Serum monoamine oxidase in thyroid diseases (author's transl)]
Thyroiditis
Monoamine oxidase (MAO) activity and its forms in normal and pathological human thyroid tissues.
Thyrotoxicosis
Blood platelet monoamine oxidase and acetylcholinesterase in thyrotoxicosis.
[Liver and heart mitochondrial monoamine oxidase activity in experimental thyrotoxicosis]
[Study of monoamine oxidase activity in the blood plasma in thyrotoxicosis]
Tics
Corrigendum to "gender in obsessive-compulsive disorder: clinical and genetic findings" [Eur. Neuropsychopharmacol. 14 (2004) 105-113].
Gender in obsessive-compulsive disorder: clinical and genetic findings.
Tonsillitis
[Serotonin and histamine content and the monoamine oxidase and diamine oxidase activities in the palatine tonsil in compensated and decompensated forms of chronic tonsillitis]
Tourette Syndrome
Enzyme activity in Tourette's syndrome.
Family-based association study between monoamine oxidase A (MAOA) gene promoter VNTR polymorphism and Tourette's syndrome in Chinese Han population.
Monoamine oxidase and catechol-O-methyltransferase activities in cultured fibroblasts and blood cells from children with autism and the Gilles de la Tourette syndrome.
Toxemia
[Study on serotonin metabolism in toxemia of pregnancy]
Tremor
5-Hydroxytryptamine-mediated behaviour in male and female rats.
Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
Blockade of central beta-adrenoceptors attenuates tremor induced by 5-hydroxytryptamine (5-HT)-receptor activation in rats.
Contrasting local effects of MAO inhibitors on caudate tremor activities.
Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications.
Drug concentrations in neuropsychiatry: alternative approaches.
Drugs for Parkinson's disease.
Future directions in the treatment of Parkinson's disease.
Harmine tremor after brain monoamine oxidase inhibition in the mouse.
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Morphological and functional studies on the serotoninergic innervation of the inferior olive.
Pharmacological characteristics of abnormal behavior induced by harmine with special reference to tremor in mice.
The inhibition of A and B forms of MAO in the production of a characteristic behabioural syndrome in rats after 1-tryptophan loading.
The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
Tuberculosis
Novel pyridazino[4,3-b]indoles with dual inhibitory activity against Mycobacterium tuberculosis and monoamine oxidase.
[Biogenic amine deamination in experimental tuberculosis]
[IDENTITY OF BEHAVIOR IN VITRO WITH RESPECT TO MYCOBACTERIUM TUBERCULOSIS OF INH AND NIALAMIDE, THYMOANALEPTIC MONOAMINE OXIDASE INHIBITORS (DEDUCTIONS OF BIOLOGICAL AND THERAPEUTIC ORDER).]
Turner Syndrome
The development of mental state attributions in women with X-monosomy, and the role of monoamine oxidase B in the sociocognitive phenotype.
Uremia
[Monoamine oxidase activity in patients with chronic renal failure and in experimental uremia in rats]
Ureteral Obstruction
Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model.
Urinary Bladder Neck Obstruction
Decreased Monoamine Oxidase a Expression and Activity in the Bladders of Rats with Partial Outlet Obstruction.
Urinary Bladder Neoplasms
Mao-a enzyme binding in bladder-cancer characterized with [C-11] harmine in frozen-section autoradiography.
Urinary Bladder, Overactive
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Urinary Incontinence
A Nationwide Survey of Parkinson's Disease Medicines Availability and Affordability in Nigeria.
Uterine Cervical Neoplasms
Invasive Cervical Cancer and Antidepressants: A Nationwide Population-Based Study.
Uterine Inertia
[Activity of mitochondrial monoamine oxidase and catecholamine content in the placenta of women in normal labor and in primary uterine inertia]
Vascular Diseases
Monoamine oxidase inhibitors and vascular disease.
Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta.
Vascular Headaches
[Treatment of vascular headaches with nialamide, a monoamine oxidase inhibitor.]
Vascular Ring
CONTRIBUTION OF MONOAMINE OXIDASES TO VASCULAR OXIDATIVE STRESS IN PATIENTS WITH END-STAGE RENAL DISEASE REQUIRING HEMODIALYSIS.
Monoamine oxidase is a source of oxidative stress in obese patients with chronic inflammation 1.
Vasoplegia
Serotonin syndrome after cardiopulmonary bypass: a case demonstrating the interaction between methylene blue and selective serotonin reuptake inhibitors.
Ventricular Dysfunction
Mitochondrial 4-HNE derived from MAO-A promotes mitoCa2+ overload in chronic postischemic cardiac remodeling.
p53-PGC-1? Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice.
Ventricular Dysfunction, Left
Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload.
p53-PGC-1? Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice.
Vertigo
Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Virus Diseases
Studies of platelet monoamine oxidase activity in Epstein-Barr and dengue virus infections.
Vitamin B 12 Deficiency
[Monoamine oxidase activity in rat liver in vitamin B12 deficiency]
Vitiligo
In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase.
Increased monoamine oxidase A activity in the epidermis of patients with vitiligo.
Whooping Cough
Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration.
Xanthomatosis, Cerebrotendinous
Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.